CURRICULUM VITAE

Medhat M. Osman, MD, ScM, PhD

PERSONAL INFORMATION

Citizenship: USA
Marital Status: Married
Number of children: Two

Office Address: Saint Louis University
Department of Radiology
Division of Nuclear Medicine
3635 Vista Avenue, 2-DT
St. Louis, MO 63110
mosman@slu.edu
314-977-8047

CURRENT HOSPITAL APPOINTMENTS

Saint Louis University Hospital
St. Louis, MO

Cardinal Glennon Childrens’ Hospital
St. Louis, MO

VA St. Louis Healthcare System
St. Louis, MO

CURRENT ACADEMIC POSITIONS

Professor, Tenured Director, Division of Nuclear Medicine & PET/CT Imaging
Nuclear Medicine Training Program Director
Department of Radiology
Division of Nuclear Medicine
Saint Louis University School of Medicine
St. Louis, MO

Nuclear Medicine Staff Physician Department of Diagnostic Imaging
John Cochran Veterans Administration Hospital St. Louis, MO

Director Master’s Degree Program
Medical Advisor Nuclear Medicine Technology Program
Department of Medical Imaging and Radiation Therapeutics
Doisy College of Health Sciences
Saint Louis University
St. Louis, MO
EDUCATION

1979-1985 MBBCH (MD degree), Assiut University Hospital; Egypt.

1987-1990 Sc M, “Development, validation, and application of a calibration procedure for quantification of film-based bone scans,” The Johns Hopkins University, School of Hygiene and Public Health, Department of Environmental Health Sciences, Division of Radiation Health Sciences and Nuclear Medicine; Baltimore, MD.

1990-1997 PhD, “The relationship between soft tissue and bone tumor response to antineoplastic therapy: Development and validation of serial quantitative bone scanning in animals and patients,” The Johns Hopkins University, School of Hygiene and Public Health, Department of Environmental Health Sciences, Division of Radiation Health Sciences and Nuclear Medicine; Baltimore, MD.

POSTGRADUATE TRAINING

1985-1986 Intern, Assiut University Hospital, Assiut, Egypt.

1986-1987 Resident, Department of Oncology and Nuclear Medicine, Assiut University Hospital, Assiut, Egypt.

1998-1999 Post–Doctoral Fellow, The Johns Hopkins Oncology Center, Baltimore, MD.

1999- 2001 Resident, Division of Nuclear Medicine, The Johns Hopkins Hospital,
Baltimore, MD.

2001- 2002 PET/CT Fellow, Division of Nuclear Medicine, The Johns Hopkins Hospital, Baltimore, MD.

2016-2017 Sabbatical, Therasphere training, Centre for Molecular Imaging at the Peter MacCallum Cancer Center, Department of Medicine, University of Melbourne, Australia (3 months)

PROFESSIONAL EXPERIENCE

1991-1997 Registry Coordinator, The National Familial Brain Tumor Registry at The Johns Hopkins Oncology Center, Baltimore, MD.

1994-1995 Registry Coordinator, The National Familial Pancreatic Tumor Registry at The Johns Hopkins Oncology Center, Baltimore, MD.

2002-2003 Acting Director, Department of Internal Medicine, Division of Nuclear Medicine, Saint Louis University, St. Louis, MO.

2002-2007 Director of PET/CT Imaging, Department of Internal Medicine, Division of Nuclear Medicine, Saint Louis University, St. Louis, MO.

2007-Present Director, Division of Nuclear Medicine & PET/CT Imaging, Department of Radiology, Saint Louis University, St. Louis, MO.

Director, Nuclear Medicine Training Program, Department of Radiology, Division of Nuclear Medicine, Saint Louis University, St. Louis, MO.

ACADEMIC APPOINTMENTS

2002- 2007 Assistant Professor (Tenure Track), Department of Internal Medicine, Division of Nuclear Medicine, Saint Louis University, St. Louis, MO.

2006-2013 Assistant Professor, Department of Molecular Imaging and Radiation
Therapeutics, Doisy College of Health Sciences, Saint Louis University, St. Louis, MO.

2007-2011 Associate Professor (Tenured), Department of Radiology, Division of Nuclear Medicine, Saint Louis University, St. Louis, MO.

2011-Present Professor (Tenured), Department of Radiology, Division of Nuclear Medicine, Saint Louis University, St. Louis, MO.

2013-Present Professor, Department of Molecular Imaging and Radiation Therapeutics, Doisy College of Health Sciences, Saint Louis University, St. Louis, MO.

HONORS AND AWARDS

1985 Public Health Award, Assiut University Hospital, Assiut, Egypt.
1987 Scholarship from UNEP (United Nation Environment Program), United Nations, New York, NY.
1993 Student Representative, Department of Environment Health Sciences, Student Assembly, The Johns Hopkins University, School of Hygiene and Public Health, Baltimore, MD.
1994 Student Representative, Committee of Human Research, The Johns Hopkins University, School of Hygiene & Public Health, Baltimore, MD.
2002 Radiology Fellow Research Award, Department of Radiology, The Johns Hopkins University, Baltimore, MD. Clinically significant inaccurate localization of lesion with PET-CT: Frequency in 300 patients.
2004 Caring Physician Award, Saint Louis University Hospital, St. Louis, MO.
2004 Included in Dr. Henry Wagner’s Highlight Lecture: Prevalence and Patterns of Physiologic Lower Extremities Uptake Detected with True Whole-Body F18 FDG-PET
2005 3rd Place presentation at Society of Nuclear Medicine annual meeting (Ryan Jackson, technologist) Prevalence and Patterns of Physiologic Muscle Uptake Detected with True Whole Body 18F-FDG PET/CT.
2005 Included in Dr. Henry Wagner’s Highlight Lecture: (Nghi Nguyen, Assistant Professor) Prevalence and Patterns of Soft Tissue Metastases: Detection with True Lecture Whole Body F-18 FDG PET/CT.
2006 1st Place presentation at Society of Nuclear Medicine annual meeting (Meghan Blasé, student section) Patterns of uptake in the subareolar plexus as detected by 18F-FDG PET/CT: Does gender or bra use matter?
2006 3rd place presentation at Society of Nuclear Medicine annual meeting (Scott Huston, student section) Warm Blanket: A simple common sense solution to the problem of FDG uptake in brown adipose tissue.
2006 2nd Place Presentation at Society of Nuclear Medicine annual meeting (Ryan Jackson, student section) Prevalence and Patterns of Physiologic Muscle Uptake Detected with Whole-Body 18F-FDG PET, J Nucl Med Technol 34: 29-33.
2006 Junior Faculty Development Award, Department of Internal Medicine, Saint Louis University, St. Louis, MO.
2007 President-Elect, Missouri Valley Chapter, Society of Nuclear Medicine.
2007 3rd Place First Annual Resident Research Poster Competition, (Nghi Nguyen, PET fellow) Saint Louis University
2007 2nd Place presentation at Society of Nuclear Medicine annual meeting (Cyrus Teymouri, student section) FDG dose extravasation in PET/CT: Frequency and impact on SUV measurements
2007 3rd Place presentation at Society of Nuclear Medicine annual meeting (David Phegley, technologist section) Challenges and Solutions for I-131 Therapy in Complex Inpatient with Thyroid Cancer: A Technologist Perspective
2009 President, Missouri Valley Chapter, Society of Nuclear Medicine.
2009 Best Doctors ’09, St. Louis, MO
2009 1st Place presentation at Society of Nuclear Medicine annual meeting (Chris Nation, student section) Impact of head holder in reducing misregistration in the area of the head and neck on PET/CT
2009 Included in Dr. Henry Wagner’s Highlight Lecture (Razi Muzaffar, resident) Incidental Diagnosis of Thrombus Within an Aneurysm in FDG PET/CT: Lecture Frequency in 926 Patients
2010 Best Doctors ’10, St. Louis, MO
2011 Best Doctors ’11, St. Louis, MO
2011 1st Place presentation at Society of Nuclear Medicine annual meeting (Amina Turnadzic, student section) Same day appointments after PET/CT: A potential radiation exposure to medical personnel and general public.
2012 Best Doctors ’12, St. Louis, MO
2013 1st Place presentation at Society of Nuclear Medicine annual meeting (Katie Yoder, student section) Development and Validation of Simple Methods to Reduce Radiation Exposure from FDG PET.CT MPI Studies
2013 2nd Place presentation at Society of Nuclear Medicine annual meeting (Dina Helina, student section) Comparison of Radiation Dose for 18-F FDG PET/CT Imaging and the Effect of Varying Protocols on Image Interpretation
2013 3rd Place presentation (Chris Kirchgesner, student section) The Variability of CT Techniques and Radiopharmaceutical Dose for SPECT/CT MPI Studies,
2013 Best Doctors ’13, St. Louis, MO
2014 2nd place Oncology Award at Society of Nuclear Medicine annual meeting
(J. Wahidi, student presentation) Y-90Sir-Sphere treatment of liver cancer and alternative imaging methods. St. Louis, Missouri, June 2014
2014 1st place Overall Award and winner of a $1000 travel stipend to attend the XI Congress of the World Federation or Nuclear Medicine and Biology, August 27- 31, 2014 in Cancun, Mexico
2014 Best overall paper and award from the Oncology Council, (A Havrilla, student presentation) Y-90Sir-Sphere treatment of liver cancer and alternative imaging methods. Society of Nuclear Medicine annual meeting, June, 2014
2014 3rd Place, Young Professionals Committee (YPC), Best Clinical Paper, (Osama Raslan, MD, resident submission) at Society of Nuclear Medicine & Molecular Imaging annual meeting, June 2014
2014 Best Doctors ’14, St. Louis, MO
2014 “RSNA On-the-Air” radio program, 100th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), Estimated audience” 43,800
2015 Editor’s Choice Awards, (Aaron Ferguson, Jonathan McConathy, Yi Su, Richard Laforest, students), Attenuation Effects of MR Headphones During Brain PET/MR Studies" ERF-Society of Nuclear Medicine and Molecular Imaging annual meeting, June, 2015
2015 2nd Place, Cardiovascular Oral Presentation Award (Hannah Sweet, student), The validity of Using Low Dose CT from FDG PET/CT Scans to Obtain Calcium Scores and Determine Patient Treatment", Society of Nuclear Medicine & Molecular Imaging annual meeting, June 2015
2016 Nominated, Career Development Enhancement Award, Veterans Administration Medical Center, St. Louis, MO

MEDICAL LICENSURE:

Missouri: Active, #2002018256

BOARD CERTIFICATION:

2002 The American Board of Nuclear Medicine, #07202
2011 The American Board of Nuclear Medicine Recertification (10/7/11-12/31/22), #07202

PROFESSIONAL MEMBERSHIPS AND SCIENTIFIC SOCIETIES:

Society of Nuclear Medicine (SNM) (1998-present)
European Association of Nuclear Medicine (EANM) (2004-present)
Academy of Molecular Imaging (AMI) (2004-present)
Radiologic Society of North America (RSNA) (2004-present)
Egyptian Society of Nuclear Medicine Specialists (ESNMS) (2004-present)
Missouri Valley Chapter, Society of Nuclear Medicine. (MVC) President (2009-2011)
CyberKnife Society (2005-2009)
American Society of Nuclear Cardiology (2013-present)

COMMITTEE MEMBERSHIPS:

Saint Louis University:

Member, Radiation Safety Committee
Member, Nuclear Medicine Technology Advisory Board
Member, Cancer Committee
Member, Credentialing and Promotions Committee
Member, International Faculty and Staff Association
Member, Department of Radiology Promotions Committee
Presenter, Annual Radiology/Nuclear Medicine Conferences and Board Reviews

National:

Society of Nuclear Medicine and Molecular Imaging, Academic Council
Society of Nuclear Medicine and Molecular Imaging, Coding and Reimbursement Committee
Society of Nuclear Medicine and Molecular Imaging, PET Center of Excellence
Society of Nuclear Medicine and Molecular Imaging, Missouri Valley Chapter

SCIENTIFIC REVIEW COMMITTEES:

2004-2006, 2008, 2010-2014, 2016 Abstract Reviewer
2017 Society of Nuclear Medicine and Molecular Imaging Annual Scientific Sessions
2004-2005, 2008-2010, 2013, 2016 Scientific Session Moderator
Society of Nuclear Medicine and Molecular Imaging Annual Meetings
2016 Sessions Chair
Society of Nuclear Medicine and Molecular Imaging Annual Meeting
2017 Chair Moderator, Musculoskeletal Session
Society of Nuclear Medicine and Molecular Imaging Annual Meeting

EDITORIAL BOARD:

Journal of Nuclear Medicine and Molecular Imaging (2005 – 2015, 2016-present)
Egyptian Journal of Nuclear Medicine (2005 – present)
Frontiers in Cancer Imaging and Diagnosis (2010 – present)
American Journal of Nuclear Medicine and Molecular Imaging (2010 – present)

ACTIVE IRB PROTOCOLS AT SAINT LOUIS UNIVERSITY:

Principal Investigator:

IRB 24077: Retrospective Analysis of Brown Fat appearance in PET/CT scans

IRB 24186: Retrospective Analysis of SPECT/CT and PET/CT data performed at SLU hospital

IRB 25023: Radium-223/ Study 16913/REASSURE – Radium-223 alpha emitter agent in safety study in mCRPC population for long-term evaluation drug or compound – Bayer HealthCare Pharmaceuticals, Inc.

Co-Investigator:

IRB 13346: Collection of Blood, Bone Marrow and Tissue Samples From Subjects with Biopsy-Proven or Suspected Malignancy and From Healthy Volunteers for a Cancer Research procurement repository; Principal Investigator: Mark Varvares, MD

IRB 15250: Prospective Evaluation of Cyberknife Stereotactic Radiosurgery for Low and Intermediate Risk Prostate Cancer: Homogenous Dose Distribution; Principal Investigator: Bruce Walz, MD
IRB 15919: Evidence Based Multimodal Neurodiagnostic Imaging of Traumatic Brain Injury and Post-Traumatic Stress Disorder; Principal Investigator: Richard Bucholz, MD

IRB 23765: A retrospective review of outpatient vs inpatient gastric emptying studies by comparing clinical scenarios and administration of medications that could alter gastric motility. Principal Investigator: Christine Hachem, MD

IRB 24173: A Survey of Head and Neck Cancer; Principal Investigator: Mark Varvares, MD

IRB 24500: Evaluation of Student Critical Reflections in the Radiologic Science; Principal Investigator: William Hubble

IRB 25092: VTEU Protocol #DMID 12-0096, “Use of PET/CT Scan to Detect In Vivo Dissemination of A BCG Challenge Strain” Purpose: To determine if PET/CT scan can be used as a noninvasive assessment of dissemination of BCG from an intradermal challenge site to local and distant lymph nodes and other tissues, which could be used to assess in vivo immunity induced by new TB vaccines; Principal Investigator: Dan Hoft, MD

ACTIVE IRB PROTOCOLS AT VA ST. LOUIS HEALTHCARE SYSTEM:

Principal Investigator:

Radium-223/ Study 16913/REASSURE – Radium-223 alpha emitter agent in safety study in mCRPC population for long-term evaluation drug or compound; Bayer Pharmaceuticals, Inc.

OPEN/CURRENT RESEARCH GRANT SUPPORT AT SAINT LOUIS UNIVERSITY:

Principal Investigator:

Radium-223/ Study 16913/REASSURE – Radium-223 alpha emitter agent in safety study in mCRPC population for long-term evaluation drug or compound – Bayer HealthCare Pharmaceuticals, Inc.

Patterns and Prevalence of FDG Extravasation in PET/CT Scans – Lucerno Dynamics; $50,000

Co-Investigator:

Evidence Based Multimodal Neurodiagnostic Imaging of Traumatic Brain Injury and Post-Traumatic Stress Disorder at the SLU Advanced Neurosurgical Innovation Center (SANIC). Total: $5.3 Million;
10% effort, $19,100.00 annually

VTEU Protocol #DMID 12-0096, “Use of PET/CT Scan to Detect In Vivo Dissemination of A BCG Challenge Strain” Purpose: To determine if PET/CT scan can be used as a noninvasive assessment of dissemination of BCG from an intradermal challenge site to local and distant lymph nodes and other tissues, which could be used to assess in vivo immunity induced by new TB vaccines. $66,700

PENDING RESEARCH GRANT SUPPORT AT SAINT LOUIS UNIVERSITY

Metabolic/morphologic changes in the brain and other organs in patients who have undergone an MRI with gadolimium contrast – General Electric, $100,000; Submitted: May, 2017

Prospective Comparison of Pelvic CT or MRI Plus 18F-NaF PET/CT to 18F-Fluciclovine PET/CT in VA Prostate Cancer Patients with BCR and a Negative 99mTc-MDP Bone Scan – Blue Earth Diagnostics, $100,000; Approved: Contract Pending

PRIOR RESEARCH GRANT SUPPORT AT SAINT LOUIS UNIVERSITY:

Philips “Added Value of True Whole-body PET/CT in Oncology:
Principal Investigator: Medhat M. Osman, MD, ScM, PhD
July 2004-2007, $600,000

E+ Healthcare “Added Value of FRG PET/CT in Prostate Cancer”
Principal Investigator: Medhat M. Osman, MD, ScM, PhD
December 2007, $30,000

Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trials of Bapineuzumab (AAB-001, ELN115727) in Patients with Mild to Moderate Alzheimer’s Disease Who Are Apolipoprotein Ee4 Non-Carriers (301) or Carriers (302). (Janssen Alzheimer Immunotherapy), 2011-2012. $6,000/year. Principal Investigator: George Grossberg.

A Randomized Study Comparing 18F-Fluoride PET/CT to Conventional Bone Imaging for Detecting Cancer that has Spread to the Bones, Principal Investigator: Medhat M. Osman, MD, ScM, PhD
2011-2014; $25,000

Sirtex Study/Quest, Principal Investigator: Medhat M. Osman, MD, ScM, PhD
2013; $10,000

PRIOR RESEARCH GRANT SUPPORT AT VA ST. LOUIS HEALTHCARE SYSTEM:

A Randomized Study Comparing 18F-Fluoride PET/CT to Conventional Bone Imaging for Detecting Cancer that has Spread to the Bones, Principal Investigator: Medhat M. Osman, MD, ScM, PhD
2011-2014

Feasibility and Diagnostic Accuracy of Myocardial SPECT Using Early Imaging Protocol: A Pilot Study. $130,000

GRADUATE/MEDICAL STUDENT SUPERVISION:

2008 Graduate Student Supervision: Mohamed H.M. Sayed
Degree Program: PhD
University: Assiut University, Assiut, Egypt
Title: Added Value of PET/CT in Patients with Cancer of Unknown Primary.
Type of Supervision: Primary advisor

2015-2016 Molecular Imaging and Therapeutics Master’s Degree Program Students:
Tibor Bauer
Nalini Patrice Daniel
Kyle Davis
Laura Christine Fohne
Hilary Michelle Lashmett
Alaina Mae Lathrum

2016 Oncology Fellow:
Craig Siegel (2nd year)

2016 Medical Students:
Isaac Tran (4th year)
Benson Lan (4th year)
Aaron Schenone (2nd year)

PUBLICATIONS:

Manuscripts (Refereed Journals):

1. Sostre S, Osman MM, Farschi KP, Civelek AC, Drew H, Szabo Z, Camargo EE, Wagner HN. “Estimating renal function from the visual analysis of Tc-99m DTPA images.” Clinical Nuclear Medicine, 1993; 18(4): 281-285.

2. Lamudue JA, Griffin AC, Osman MM, Hruban RH. “Familial pancreatic cancer and the genetics of pancreatic cancer.” Surg. Clin. N. Amer, 1995; 75(5):845-855.

3. Williams JR, Zhang Y, Zhou H, Osman MM, Song S, Kavet R, Cuccinotta F, Dicello JF, Dillehay LE. “Predicting cancer rates in astronauts from animal carcinogenesis studies and cellular markers.” Journal of Mutation Research, 1999; 430(2): 255-269.

4. Grossman SA, Osman MM, Hruban R, Piantadosi S. Central nervous system malignancies in first degree family members and spouses. Cancer Investigation, 1999; 17(5):299-308.

5. Nakamoto Y, Osman MM, Cohade C, Marshall L, Links J, Kohlmyer S, Wahl R. PET/CT: Comparison of quantitative tracer uptake between germanium and CT transmission attenuation correction maps. JNM, 2002; 43:1137-1143.

6. Chin BB, Patel PV, Cohade C, Osman MM, Wahl RL. Quantitative evaluation of 2-Deoxy-2 [18F] Fluoro-D-Glucose uptake in Hepatic metastases with combined PET-CT: Iterative reconstruction with CT attenuation correction versus filtered back projection with 68Germanium attenuation correction. Molecular Imaging and Biology, 2002; 4 (6):399-409.

7. Osman MM, Cohade C, Nadamoto Y, Wahl R. Clinically significant inaccurate localization of lesion with PET-CT: Frequency in 300 patients. JNM, 2003; 44(2): 240-243.

8. Cohade C, Osman MM, Pannu H, Wahl R. Uptake in the Supraclavicular area fat (“USA- Fat”): Description on FDG PET/CT. JNM, 2003; 44(2): 170-176.

9. Cohade C, Osman MM, Nakamoto Y, Wahl R. Initial experience with oral contrast in PET-CT: phantom and clinical studies. JNM, 2003; 44(3): 412-416.

10. Nakamoto Y, Cohade C, Osman MM, Marshal L, Wahl R. Accuracy of image fusion of normal upper abdominal organs visualized with PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2003; 30(4):597-602.

11. Osman MM, Cohade C, Nakamoto Y, Wahl RL. Respiratory motion artifacts on PET emission images obtained using CT attenuation correction on PET-CT. European Journal of Nuclear Medicine and Molecular Imaging, 2003; 30(4):603-606.

12. Nakamoto Y, Osman MM, Wahl R. Prevalence and patterns of Bone Metastases in clinical FDG-PET. Journal of Clinical Nuclear Medicine, 2003; 28(4):302-307.

13. Cohade C, Osman MM, Pannu H, Wahl R. Accuracy of PET and CT spatial registration of lung lesions. European Journal of Nuclear Medicine and Molecular Imaging, 2003; 30(5): 721-726.

14. Cohade C, Osman MM, Leal J, Wahl R. Direct comparison of FDG PET and PET-CT in patients with colorectal carcinoma. JNM, 2003; 44(11): 1797-1803.

15. Nakamoto Y, Chin BB, Cohade C, Osman MM, Wahl RL. PET/CT: Artifacts caused by bowel motion. Nucl Med Commun, 2004; 25(3):221-225.

16. Hogan RE, Kaiboriboon K, Osman MM. Composite SISCOM images in mesial temporal lobe epilepsy: Technique and illustration of regions of hyperperfusion. Nucl Med Commun, 2004; 25(6):539-545.

17. Kaiboriboon K, Bertrand ME, Osman MM, Hogan RE. Quantitative Analysis of Cerebral Blood Flow Patterns in Mesial Temporal Lobe Epilepsy Using Composite SISCOM, JNM, 2005; Jan 46(1):38-43.

18. Nakamoto Y, Hammoud D, Cohade C, Osman MM, Wahl RL. Normal distribution patterns of FDG in the head and neck: PET/CT evaluation. Radiology, 2005; 234(3):879-885.

19. Osman MM, Cohade C, Fishman E, Wahl RL. Clinically Significant Incidental Finding on Non-Contrast CT Portion of PET/CT Studies: Frequency in 250 Patients. JNM, 2005; 46(8):1352-1355.

20. Civelek AC, Piotrowski B, Osman MM, Memisoglu E, Khayyat N, Reimers HJ, Naunheim KS. When the Cancer is Skin Deep. Annals of Nuclear Medicine, 2006; 20 (2):147-149.

21. Jackson RS, Schlarman JC, Hubble WL, Osman MM. "Prevalence and Patterns of Physiologic Muscle Uptake Detected with Whole-Body 18F-FDG-PET". Journal of Nuclear Medicine Technology, 2006; 34(1):29-33.

22. Mamelak AN, Rosenfeld S, Bucholz R, Fiveash JB, Shen S, Khazaeli MB, Liu A, Osman MM, Guthrie B, Hablitz BM, Alvarez VL, Gonda VA. “Phase I/II Single-Dose Study of Intracavitary Administration of I-131 TM-601 in Adults with Recurrent High-Grade Glioma”. Journal of Clinical Oncology, 2006; 24(22): 3644-3650.

23. Ziari M, Kudva GC, Salinas-Madrigal L, Cortese C, Garvin P, Osman MM, Bastani B. Late occurrence of malignant post-transplant lymphoproliferative disorder (PTLD) presenting with severe acute renal failure. Dialysis & Transplantation, 2007; 36(5):276-282.

24. Botkin C, Osman MM. Prevalence, Challenges and Solutions for F-18 FDG PET Imaging of Obese Patients: A Technologist Prospective. J Nucl Med Technol, 2007; 35(2):80-83.

25. Nguyen N, Chaar BT, Osman MM. Prevalence and patterns of soft tissue metastases: Detection with true whole-body F-18 FDG PET/CT. BMC Medical Imaging, 2007; 7:8.

26. Nguyen N, Chaar BT, Osman MM. Spinal Cord Metastases from Lung Cancer: Detection with F-18 FDG PET/CT. Journal of Clinical Nuclear Medicine, 2008; 33(5):356-8.

27. Aygen M, Akduman IE, Osman MM. Bladder Ear: A Potential Source of False Interpretation on F-18 FDG PET. Clinical Nuclear Medicine, 2008; 33(10):1-2.

28. Hueser CN, Nguyen NC, Osman MM, Havlioglu N, Patel AJ. Extrapulmonary Small Cell Carcinoma Involvement of the Brain without Evidence of Extracranial Malignancy by Serial PET/CT Scans. World Journal of Surgical Oncology, 2008; 6:102.

29. Nguyen NC, Akduman IE, Sayed MH, Oliver D, Osman MM. Increased 18-F-FDG Uptake in the Posterior Ocular Bulb Is Associated with Brain Metastasis: A Retrospective Study. Am. J. Roentgenol. 2008; 191:268-274.

30. Reinking MF, Osman MM. Prospective Evaluation of Physiologic Uptake Detected With True Whole-Body 18F-FDG PET-CT in Normal Subjects. JNMT 2009; 37:31-37.

31. Nguyen NC, Tran I, Hueser CN, Oliver D, Farghaly HR, Osman MM. F-18 FDG PET/CT Characterization of Talc Pleurodesis-Induced Pleural Changes Over Time: A Retrospective Study. Clin Nucl Med 2009; 34(12):886-890.
32. Farghaly HR Muzaffar R, Bohle RJ, Nguyen NC, Osman MM. Patterns and Prevalence of Misregistration in 18F-FDG PET/CT. Egyptian Journal of Nuclear Medicine 2009; 2(2):55-64.

33. Sayed MH, Farghaly HR, Nguyen NC, Mustafa MS, Mekkawy MA, Osman MM. Extrapulmonary Small Cell Carcinoma in Prostate Detection with F-18 FDG PET/CT. Clin Nucl Med. 2010; 35(1):38-39.

34. Moinuddin A, Nguyen NC, Osman MM. Careful evaluation of CT findings of a cardiac viability F-18 FDG PET/CT study leading to detection of esophageal cancer. Clin Nucl Med. 2010 May; 35(5):335-7.

35. Nguyen NC, Hueser CN, Kaushik A, Farghaly HR, Osman MM. F-18 fluorodeoxyglucose positron emission tomography/computed tomography findings of an unusual breast lymphoma case and concurrent cervical cancer: a case report. Journal of Medical Case Reports, 2010; 4:282.

36. Huston SF, Abdelmalik AG, Nguyen NC, Farghaly HR, Osman MM. Whole-body 18F FDG-PET/CT: The need for a standardized field of view, a referring physician aid. JNMT, 2010; 38:123–127.

37. Osman MM, Chaar, BT, Muzaffar R, Oliver D, Reimers HJ, Walz B, Nguyen NC. 18F-FDG PET/CT of Patients With Cancer: Comparison of Whole-Body and Limited Whole-Body Technique. AJR 2010; 195(6):1397-403.

38. Abdelmalik AG, Fajnwaks P, Osman MM, Nguyen NC. Squamous Cell Carcinoma of the Bulbar Conjunctiva Seen on F-18 FDG PET/CT. Clin Nucl Med. 2010; 35(12):962-4.

39. Osman MM, Altinyay ME, Abdelmalik AG, Brickman TM, Varvares MA, Nguyen NC.
FDG PET/CT Incidental Diagnosis of a Synchronous Bladder Cancer as a Fourth Malignancy in a Patient With Head and Neck Cancer Clin Nucl Med. 2011; 36(6):496-7.

40. Nguyen N, Kaushik A, Wolverson M, Osman MM. Is there a common SUV threshold in oncological FDG PET/CT, at least for some common indications? A retrospective study. Acta Oncologica 2011; 50(5):670-7.

41. Osman MM, Altinyay ME, Abdelmalik AG, Brickman TM, Varvares MA, Nguyen NC. FDG PET/CT incidental diagnosis of a synchronous bladder cancer as a fourth malignancy in a patient with head and neck cancer. Clin Nucl Med. 2011; 36(6):496-7.

42. Osman MM, Tran IT, Parkar N, Sachdeva A, Ruppel G, and Nguyen NC. Does 18F-FDG Uptake of Respiratory Muscles on PET/CT Correlate with Chronic Obstructive Pulmonary Disease Diagnosis? JNMT 2011; 39:252-57.

43. Muzaffar R, Kudva G, Nguyen NC, Osman MM. Incidental Diagnosis of Thrombus Within an Aneurysm on 18F-FDG PET/CT: Frequency in 926 Patients. J Nucl Med. 2011; 52(9):1408-11.

44. Osman MM, Muzaffar R, Altinyay ME, Teymouri C. FDG dose extravasations in PET/CT: frequency and impact on SUV measurements. Frontiers in Oncology, 2011; 1(41):1-6.

45. Fesler MJ, Osman MM, Glauber J, Petruska PJ. C-MOPP: the forgotten regimen plus Rituximab for untreated and relapsed follicular lymphoma. Am J Blood Res, 2011; 1(2):204-14.
46. Muzaffar R, Shousha MA, Sarajlic L, Osman MM. Ophthalmologic abnormalities on FDG-PET/CT: a pictorial essay. Cancer Imaging. 2013 Mar 21;13:100-12.
47. Abdelmalik AG, Alenezi S, Muzaffar R, Osman MM. The Incremental Added Value of Including the Head in (18)F-FDG PET/CT Imaging for Cancer Patients. Front Oncol. 2013 Apr 4;3:71.
48. Allam T, Muzaffar R, Nguyen NC, Osman MM. Peritoneal Mouse as Detected on (18)F-FDG PET-CT. Front Oncol. 2013 Apr 10;3:83.
49. Muzaffar R, Fesler M, Osman MM. Active Shingles Infection as Detected on (18)F-FDG PET/CT. Front Oncol. 2013 Apr 24;3:103
50. Dunsky KA, Wehrmann DJ, Osman MM, Thornberry BM, Varvares MA. PET-CT and the detection of the asymptomatic recurrence or second primary lesions in the treated head and neck cancer patient. Laryngoscope. 2013 Sep;123(9):2161-4.
51. Farmakis S, Vejdani K, Muzaffar R, Parkar N, Osman MM. Detection of Metastatic Disease in Cardiophrenic Lymph Nodes: FDG PET/CT Versus Contrast-Enhanced CT and Implications for Staging and Treatment of Disease. Front Oncol. 2013 Oct 1;3:260.
52. Havrilla A, Raslan O, Muzaffar R, Botkin C, Hubble W, Hewing D, Sayed M, Osman MM. Value of Tc-99m-bicisate (ECD) balloon test occlusion in preoperative assessment of stroke risk prior to internal carotid artery sacrifice. EJNM Dec 2014
53. Ahmed F, Raslan O, Muzaffar R, Parkar N, Marwaha N, Osman MM. Sjogren Syndrome complicated by mucosa-associated lymphoid tissue lymphoma and lymphocytic interstitial pneumonia. Front Oncol. 2015 Aug; 6:5:179 doi: 10.3389/fonc.2015.00179. eCollection 2015. PMID: 26301203
54. Willowson KP, Tapner M, QUEST Investigator Team, Bailey DL. A multicenter comparison of quantitative (90)Y PET/CT for dosimetric purposes after radioembolization with resin microspheres: The QEST Phantom Study. Eur J Nucl Med Mol Imaging. 2015 Jul; 42(8):1202-22 Epub 2015 May 13. PMID:25967868
55. Muzaffar R, Raslan O, Osman MM. 18F-FDG-avid plantar nodules on true whole-body 18F-FDG PET/CT in cancer patients. Nucl Med Commun. 2015 Sept; 36(9):881-6. PMID: 25932543
56. Raslan OA, Muzaffar R, Vilaas Shetty, Osman MM. Image findings of cranial nerve pathology on [18F]-2- deoxy-D-glucose (FDG) positron emission tomography with computerized tomography (PET/CT): a pictorial essay. Cancer Imaging, 2015 Dec 3; 15(1):20. PMID: 26634826
57. Holmes S, Kim M, Prather C, Osman MM, Muzaffar R, et al. (2015) Outpatient vs. Inpatient Gastric Emptying Studies: Does Admission Status Influence Findings? J Hepatol Gastroint, 2015.
58. Raslan OA, Parkar N, Muzaffar R, Doherty C, Osman MM. Endobronchial carcinoid tumor with incidental metastatic breast cancer detected by somatostatin receptor scintigraphy (111In-diethylenetriaminepentaacetic acid octreotide). Radiology, 2016 Mar;278(3):949-55.PMID: 26885736
59. Nguyen NC, Abhishek K, Nyon S, Farghaly HR, Osman MM, Reimers HJ.
Are there radiographic, metabolic, and prognostic differences between cavitary and noncavitary nonsmall cell lung carcinoma? A retrospective fluorodeoxyglucose positron emission tomography/computed tomography study. Ann Thorac Med. 2016 Jan-Mar;11(1):49-54. PMID: 26933457
60. F. Ahmed, R. Muzaffar, H. Fernandes, Y. Tu, B. Albalooshi and Osman MM. "Skeletal Metastasis as Detected by 18F-FDG PET with Negative CT of the PET/CT: Frequency and Impact on Cancer Staging and/or Management" Front. Oncol., 10 October 2016.
61. Bauer K, Lathrum A, Raslan O, Kelly P, Zhou Y, Hewing D, Botkin C, Turner J, Osman MM. Do gadolinium-based contrast agents affect the 18F-FDG PET/CT uptake in the dentate nucleus and the globus pallidus? A pilot study. J Nucl Med Technol. 2017 Mar;45(1):30-33.
62. Hussein; A. Green; A. Watane; D. Reiter; X. Chen; G. Z. Papadakis; B. Wood; A. Cypess; M. Osman; U. Bagci, "Automatic Segmentation and Quantification of White and Brown Adipose Tissues from PET/CT Scans," in IEEE Transactions on Medical Imaging, 2017 Mar;36(3):734-744.
63. Green AL, Bagci U, Hussein S, Kely PV, Muzaffar R, Neuschwander-Tetri BA, Osman MM. Brown adipose tissue detected by Pet/CT imaging is associated with less central obesity. Nucl Med Commun, Nucl Med Commun. 2017 Jul;38(7):629-635.
64. Osman MM, Iravani A, Hofman MS, Hicks RJ: Detection of Synchronous Primary Malignancies with 68Ga-PSMA PET/CT in Patients with Prostate Cancer: Frequency in 764 Patients, J Nucl Med, 2017, Jun 1. Pii: jnumed. 117.190215. doi: 2967/jnumed.117.190215.
65. Kode V, Karsch H, Osman MM, Muzaffar R. Impact of renal failure on F18-FDG PET/CT scans. Frontiers in Oncology (In press)

Manuscripts (Invited Articles):

1. Osman MM. Whole-body FDG-PET and PET/CT cancer scanning. Discussion in PET Imaging, 2005, May.

2. Nguyen NC, Akduman I, Osman MM. F-18 FDG-PET and PET/CT Imaging of Cancer Patients. J Radiol Nurs, 2008; 27:61-69.

3. Osman MM, Varvares MA, Nguyen NC. Pictorial Essay: Non-Malignant FDG Uptake in the Head and Neck Region. PET Clin, 2008; 2:445-468.

4. Osman, MM. Striking a balance in PET imaging transforms patient care. Supplement to Applied Radiology, 2012; 32-35.

5. Muzaffar R, Osman MM. Clinical Case: Recurrent lymphoma in the left acetabulum. Supplement to Applied Radiology, 2012; 36-38.

6. Osman MM. Low-dose, high-quality SPECT/CT imaging transforms patient care. Supplement to Applied Radiology, 2012; 39-45.

7. Muzaffar R, Osman MM. Clinical Case: Osteomyelitis with associated fracture in the toe as seen on high-resolution SPECT/CT. Supplement to Applied Radiology, 2012; 46-48.

Textbook Contributions:

1. Lumadue JA, Griffin CA, Osman MM, Hruban RH. “Familial Pancreatic Cancer and the Genetics of Pancreatic Cancer” in The Surgical Clinics of North America, W.B. Saunders Company; 1995, 75(5):845-855.

2. Allman KC, Miller DD, Osman MM. “Nuclear Cardiology and Cardiac Transplantation” in Nuclear Medicine in Clinical Diagnosis and Treatment, 3rd Edition, Martin Mellor Publishing Services; Ell P, Gambhir S, (Eds.): 2004; Chapter 61:859-869.

3. Osman MM, Wall A, Miller MD, Nguyen N, Oliver D, Bucholz R, Walz BJ. “18FDG-PET/CT for Treatment Planning and Follow-Up” in Robotic Radiosurgery 2007; Treating Tumors That Move With Respiration. Harold C. Urschel, Jr. Springer.

4. Muzaffar R, Raslan O, Osman MM. (2014). "Nuclear Oncology." The Pathophysiologic Basis of Nuclear Medicine. A. Elgazzar (Ed.). Third edition. New York: Springer.

Letters to the Editors:

1. Osman MM. Whole-Body Imaging for Cancer Staging. JAMA, 2004; 17; 291(11):1320.

2. Nguyen NC, Taalab K, Osman MM. Decreased Blood Flow With Increased Metabolic Activity: A Novel Sign of Pancreatic Tumor Aggressiveness. Clin Cancer Res. 2010; 16(1):367.

3. Nguyen NC, Bhatla D, Osman MM. 123I-MIBG Scintigraphy and 18F-FDG PET in Neuroblastoma. JNM, 2010 Feb; 51(2):330-2.

4. Nguyen NC, Abdelmalik A, Moinuddin A, Osman MM. Detection of Pulmonary Embolism: Comparison of Methods. JNM, 2010; 51(5):823-4.

5. Nguyen NC, Fajnwaks P, Osman MM, Farghaly HR. 18F-FDG PET for Routine Post-treatment Surveillance in Oral and Oropharyngeal Squamous Cell Carcinoma. JNM, 2010; 51(7):1164-1165.

6. Nguyen NC, Osman MM. F18-FDG-PET/CT standardized uptake value threshold in discriminating benign vs. malignant lesions. Doubts and certainties in the era of evidence-based medicine. Acta Oncol. 2011 Mar 16.

7. Nguyen NC, Osman MM. F18-FDG-PET/CT standardized uptake value threshold in discriminating benign vs. malignant lesions. Doubts and certainties in the era of evidence-based medicine. Acta Oncol. 2012; 51(1):123-124.

8. Osman MM, Turner JA. Reply: Effect of Gadolinium Deposition on 18F-FDG PET/CT of Dentate Nucleus and Globus Pallidus. J Nucl Med Technol. 2017; Jun;45(2):173. doi: 10.2967/jnmt.117.191577. Epub 2017 Mar 9.

Abstracts:

1. Soster S, Osman MM, Farschi KP, Civelek AC, Drew H, Szabo Z, Camargo EE, Wagner HN. Characteristics of Tc-99M DTPA renal images in patients with reduced Glomerular Filtration Rate (GFR). The Society of Nuclear Medicine 37the Annual Meeting, Washington, D.C., 1990.

2. Osman MM, Grossman SA, Links J. Calibration procedure for quantification using optical densities in film - based nuclear medicine bone scans. In vivo autoradiography & correlative imaging, Chapel Hill, North Carolina, 1990.

3. Osman MM, Grossman SA, Griffin C, Hruban R, Sheidler VR, Helzlsour K, Piantadosi S. The National Familial Brain Tumor Registry (NFBTR). Proc. Am. Soc. Clin. Oncol., 1991; 10:124.
4. Osman MM, Grossman SA, Griffin C, Hruban R, Sheidler VR, Helzsouer K, Piantadosi S. The National Familial Brain Tumor Registry (NFBTR). Eighth International Congress of Human Genetics, Washington D.C., 1991.

5. Grossman SA, Griffin C, Osman MM, Hruban R, Sheidler VR, Helzsouer K, Piantadosi S. The National Familial Brain Tumor Registry. Ninth International Conference on Brain Tumor Research and Therapy, Asilomar, California, 1991.

6. Osman MM, Grossman SA, Griffin C, Hruban R, Sheidler VR. Primary brain tumors in spouses and relatives: a report from the National Familial Brain Tumor Registry (NFBTR). Proc. Am. Soc. Clin. Oncol., 1992; 11:149.

7. Osman MM, Klein J, Vreisendorp H, Quadre S, Williams J. Quantitative comparison of injected radio-immuno-conjugate persistence in blood and liver of humans and other species. Fourth Conference on Radioimmunodetection and Radioimmunotherapy of Cancer, Princeton, NJ, 1992.

8. Osman MM, Grossman SA, Links J. Quantifiable Bone scans converting bone lesions from evaluable to measurable disease. Proc. Am. Soc. Clin. Oncol., 1993; 12:117.

9. Osman MM, Lumadue J, Hruban RH, Kern S, Peterson G, Griffin C, Grossman S, Harvey B, Yeo C, Grochow L, Coleman J, Cameron J. The National Familial Pancreatic Tumor Registry NFPTR). Proc. Am. Soc. Clin. Oncol., 1994; 13:214.

10. Osman MM, Grossman SA, Links J, Eisenberger M, Kennedy J, Piantadosi S. Correlation of response in soft tissue and bone tumors in animals and patients using quantitative bone scans (QBS). Proc. Am. Soc. Clin. Oncol., 1995;14:499.

11. Grossman SA, Osman MM, Hruban RH, Piantadosi S. Familial Glimoas: the potential role of environmental exposures. Proc. Am. Soc. Clin. Oncol., 1995; 14:149.

12. Osman MM, Carducci M, Link J, Grossman SA. The relationship between soft tissue and bone tumor response to antineoplastic therapy: development and validation of serial quantitative bone scintigraphy in animals and in patients with breast and prostate cancer.
Oral presentation. The 7th Prouts Neck Meeting on Prostate Cancer, Maine, 1996.

13. Musachil JL, Brasic JR, Sheffel UA, Rauseo PA, Osman MM, Hilton J, Zhou Y, Wong DF. Radiosynthesis, in vitro/in vivo pharmacologic characterization, and initial human SPECT imaging studies with [I-123] 5-ido-A-85380: a high affinity nicotinic acetylcholine receptor (nAChR) radioprobe. 221st American Chemical Society National Meeting, San Diego, CA; April 1-5, 2001.

14. Wong DF, Brasic JR, Zhou Y, Gay O,H, Hilton J, Osman MM, Scheffel UA, Rousset O, Fan H, Dannals RF, Musachio JL. Human Imaging of &4B2 nicotinic acetylcholine receptor in vivo using [123I] 5-ido-A-85380. JNM, 2001; 42:142P.

15. Brasic JR, Musachio JL, Zhou Y, Osman MM, Gay O, Hilton J, Kuwabara H, Crabbe A, Rousset O, Fan H, Arkles JS, Thompson T, Kalaff A, Smith J, Wong DF. Neuropsychiatric assessment of [123I] ido-3-(2azetidinylmethoxy) pyridine. Movement Disorders, 2001; 16:S54.

16. Brasic J, Osman MM, Gay O, Arkles JS, Kalaff A, Belle AS, Singer HS, Wong DF. Characteristics of volunteers for neuroimaging studies of Tourettes disorder. Movement Disorders, 2001; 16:S47.

17. Chin B, Osman MM, Iyengar S, Schwartz D. Early HIV infection correlates with abnormal FDG PET uptake in the spleen. Spleenic FDG PET uptake is increased in early HIV infection. Oral presentation, European Association of Nuclear Medicine Congress Naples, Italy, Aug 2001.

18. Hales J, Yung RC, Osman MM, Cohade C, Wahl RL. Positron emission tomography (PET) in the clinical management of thoracic masses. Oral presentation, American Thoracic Society meeting, Atlanta, GA, May 2001.

19. Nakamoto Y, Osman MM, Wahl RL. Prevalence and Patterns of Bone Metastases in Clinical FDG-PET. RSNA 87th meeting, Nov. 2001.

20. Nakamoto Y, Osman MM, Cohade C, Marshall L, Links JM, Wahl RL. PET/CT: Comparison of quantitative tracer uptake between germanium and CT transmission attenuation correction maps. JNM, 2002; 43:13P.

21. Nakamoto Y, Cohade C, Osman MM, Tatsumi M, Raughber BJ, Marshal L, Wahl RL. PET/CT: Comparison of size and location of normal upper abdominal organs on PET and CT using PET/CT. JNM, 2002; 43:14P.

22. Cohade C, Osman MM, Marshall L, Wahl RL. Metallic object artifacts on PET-CT: Clinical and phantom studies. JNM, 2002; 43:308P.

23. Cohade C, Osman MM, Wahl RL. The supraclavicular FDG “Muscle” uptake artifact is often not muscle: Evaluation with PET-CT. JNM, 2002; 43:31P.

24. Patel P, Chin B, Osman MM, Marshall L, Wahl RL. Quantitative accuracy of F18_FDG uptake in metastatic liver lesions with PET CT: Iterative reconstruction with CT Attenuation correction versus iterative reconstruction and FBP with GE68 attenuation correction. JNM, 2002; 43: 214P.

25. Cohade C, Osman MM, Wahl RL. Accuracy of PET and CT spatial registration of lung lesions with PET-CT. JNM, 2002; 43:14P.

26. Osman MM, Cohade C, Leal J, Wahl RL. Direct comparison of FDG-PET and PET–CT imaging in staging and restaging patients with lung cancer. JNM, 2002; 43:151P.

27. Cohade C, Osman MM, Nakamoto Y, Marshall L, Wahl RL. Comparison of 68Ge and CT transmission maps of the thorax on PET-CT. JNM, 2002; 43:216P.
28. Osman MM, Cohade C, Fishman E, Marshall L, Clough D, Brooks G, Wahl RL. Preliminary clinical evaluation of oral contrast in PET-CT: Work in progress. JNM, 2002; 43:308P.

29. Cohade C, Osman MM, Leal J, Wahl RL. Direct comparison of FDG PET and PET-CT imaging in colorectal cancer. JNM, 2002; 43:22P.

30. Osman MM, Cohade C, Fishman E, Wahl RL. Clinically significant incidental findings on non-contrast CT portion of PET-CT studies: Frequency in 250 patients. JNM, 2002; 43:307P.

31. Osman MM, Cohade C, Nadamoto Y, Wahl RL. Clinically significant inaccurate localization of lesion with PET-CT: Frequency in 275 patients. JNM, 2002; 43:32P.

32. Cohade C, Osman MM, Marshall L, Wahl RL. Oral contrast agent induced artifacts with PET-CT: Phantom studies and clinical case observation. JNM, 2002; 43:308P.

33. Osman MM, Cohade C, Wahl RL. Respiratory motion artifacts on PET emission images obtained using CT attenuation correction on PET-CT. JNM, 2002; 43:304P

34. Kaiboriboon K, Osman MM, Bertrand ME, Willmore LJ, Hogan RE. Quantitative Analysis of Ictal Cerebral Blood Flow Patterns in Unilateral Temporal Lobe Epilepsy. JNM, 2003; 44:19P.

35. Osman MM, Nakamoto Y, Wahl RL. Pattern and Prevalence of Post-Sternotomy Sternal FDG Uptake with F-18 FDG as assessed with PET/CT. JNM, 2003; 44:96P.

36. Kohrs C, Anastas SM, Yost P, Osman MM. Patterns of Post-Injection Residual Dose of Fluorine-18-Fluorodeoxyglucose in PET Studies. Technologist section of the SNM 50th annual meeting, New Orleans, LA, June 21-25, 2003.

37. Pap DT, Osman MM, Varma CR, Solomon H. Value of Nuclear Hepatobiliary Imaging in Liver Transplant Patients Without Clinical Suspicion of Biliary Leak. Oral presentation at the 2003 Missouri Valley Chapter Annual Meeting, St. Louis, MO, Sep 11-13, 2003.

38. Osman MM, Pape DT. Pattern and Prevalence of Nasal Uptake detected using F18-FDG PET: Correlation with History of Runny Nose and National Influenza Incidence. Molecular Imaging and Biology 2004; 5(3):195P.

39. Khayyat NM, Osman MM. Added Value of True Whole Body FDG-PET Imaging in Patients with Non-Small Cell Lung Cancer. Molecular Imaging and Biology, 2004; 6(2):104P.

40. Osman MM, Khayyat N, Mosley C, Reimers H. Prevalence and Patterns of Soft Tissue Metastases from Non-small Cell Lung Cancer Detected with True Whole-body F-18 FDG-PET. RSNA Abstract book, pg. 308, 2004.

41. Osman MM, Sattah MV, Khayyat NM, Akhtar S, Reimers HJ, Naunheim KS, Civelek AC. Bone Metastases From Non-Small Cell Lung Cancer; Prevalence and Patterns Detected by True Whole body F18 FDG-PET. JNM, 2004; 45:S25.

42. Osman MM, Khayyat N, Civelek AC. Added Value of True Whole body FDG-PET Imaging in Patients with Melanoma. JNM, 2004; 45:S200.

43. Osman MM, Reinking MF, Mosley C, Khayyat N, Civelek AC. Prevalence and Patterns of Physiologic Lower Extremities Uptake Detected with True Whole-Body F18 FDG-PET. JNM, 2004; 45:S302.

44. Osman MM, Yost P, Anastas S, Botkin C, Civelek AC. True Whole Body F18 FDG-PET in Oncology; Added Value, Challenges, and Solutions. JNM, 2004; 45:S483.

45. Osman MM, Botkin C, Anastas S, Yost P, Civelek AC. Prevalence, Challenges and Solutions for F-18 FDG PET Imaging of Obese Patients. JNM, 2004; 45:S489.

46. Jackson RS, Botkin C, Anastas S, Yost P, Osman MM. Prevalence and Patterns of Physiologic Muscle Uptake Detected With Whole-Body F18 FDG-PET. JNM, 2004; 45:S499.

47. Osman MM, Jackson R, Mosley C, Khayyat N, Botkin C, Anastas S, Yost P, Civelek C. Prevalence, Challenges and Solution for F-18 FDG PET Imaging of Claustrophobic Patients. European Journal of Nuclear Medicine, 2004; 31(2):S373.

48. Mosley C, Reinking MF, Osman MM. Prevalence and Patterns of Physiologic Lower Extremity Uptake Detected with True Whole-Body F-18 FDG PET/CT. JNM, 2004; 46(2):S80.

49. Khayyat N, Akduman EI, Oliver D, Osman MM. Direct Comparison of Unenhanced CT, F18 FDG PET and PET/CT in Patients with Adrenal Lesions. JNM, 2005; 46(2):S220.

50. Mosley C, Osman MM. Prevalence and Patterns of Lymphedema Detected with True Whole-Body F-18 FDG PET/CT. JNM, 2005; 46(2):S221.

51. Nguyen NC, Hussein M, Osman MM. Prevalence and Patterns of Soft Tissue Metastases: Detection with True Whole Body F-18 FDG PET/CT. JNM, 2005; 46(2):S234.

52. Nguyen NC, Osman MM. Added Value of True Whole-Body Over Limited Whole-Body FDG PET/CT in Cancer Imaging. JNM, 2005; 46(2):S236.

53. Taschner BC, Jackson R, Osman MM, Civelek AC, Miller DD. The Highs and Lows of Cardiac TC-99M Sestamibi SPECT and MUGA Imaging Characteristics in Pre-Transplantation Hepatic Failure Patients. JNM, 2005; 46(2):S273.

54. Anastas SM, Botkin CD, Yost PE, Kallogjeri D, Osman MM. Correlation Between Myocardial Uptake and Caffeine Intake: Detection with FDG-PET/CT. JNM, 2005; 46(2):S498.
55. Yost PE, Anastas SM, Botkin CD, Osman MM. A Technologist Prospective: True Whole Body F18-FDG PET/CT in Oncology; Added Value, Challenges, and Solutions. JNM, 2005; 46(2):S501.

56. Jackson R, Anastas SM, Botkin CD, Yost PE, Osman MM. Prevalence and Patterns of Physiologic Muscle Uptake Detected with True Whole-Body F-18 FDG PET/CT. JNM, 2005; 46(2):S513.

57. Thatcher JL, Jackson R, Osman MM. Metal Artifacts Detected with Non-Contrast CT: Impact on the PET Portion of True Whole-Body F18 FDG PET/CT. JNM, 2005; 46(2):S523.

58. Huston SF, Jackson R, Osman MM. Whole-Body F-18 FDG PET/CT: The Need for Standardized Field of View. JNM, 2005; 46(2):S523.

59. Osman MM, Mosley C, El-Sadda W, Varvares M. Prevalence and Patterns of Nerve Injury in Patients With Head and Neck Cancers as Detected with F-18 FDG PET/CT. Accepted for presentation at RSNA, Chicago, November 2005.

60. Miller M, Nguyen N, Oliver D, Walz B, Osman MM. Added Value of 18F FDG-PET/CT in Cyberknife Stereotactic Radiosurgery. CyberKnife 5th annual users’ meeting, Carlsbad, CA January 2006.

61. Nguyen NC, El-Sada W, Akduman I, Oliver D, Ege G, Osman MM. PET/CT Characterization of Adrenal Lesions. JNM, 2006; 47(1):S226.

62. Tran IT, Ruppel GL, Oliver D, Osman MM. Chronic Obstructive Pulmonary Disease: Patterns of Muscle Uptake as Detected by 18F-FDG PET/CT. JNM, 2006; 47(1):S555.

63. El-Sada W, Nguyen N, Varvares MA, Walz B, Reimers H, Osman MM. Added Value of F18 FDG-PET/CT in Patients with Head and Neck Cancer: Detection of Distant Metastases and Second Primary Cancers. JNM, 2006; 47(1):S468.

64. Mosley C, Akduman I, Hussein M, Chaar BT, Kallogjeri D, Osman MM. Direct Comparison of Unenhanced CT, 18F-FDG PET and PET/CT in Patients with Low-Grade Lymphoma: Initial Experience. JNM, 2006; 47(1):S226.

65. Leonard K, Oliver D, Osman MM. Does Switching from 2D PET to 3D PET/CT Affect Radiation Doses in Patients and Technologists? JNM, 2006; 47(1):S551.

66. Thatcher JL, Osman MM. Prevalence, Challenges and Solutions for F-18 FDG PET/CT Imaging of Claustrophobic Patients. JNM, 2006; 47(1):S558.

67. Khayyat N, Osman MM. Added Value of True Whole-Body F-18 FDG PET/CT Imaging in patients with Melanoma. JNM, 2006; 47(1):S104.

68. Botkin C, Huston S, Yost P, Osman MM. Challenges and Solutions for Acquiring Diagnostic CT Studies in a Busy PET/CT Center: A Nuclear Medicine Technologist Prospective. JNM, 2006; 47(1):S558.

69. Blasé M, Oliver D, Osman MM. Patterns of Uptake in the Subareolar Plexus as Detected by 18F-FDG PET/CT: Does Gender or Bra Use Matter? JNM, 2006; 47(1):S559.

70. Nguyen NC, Hogan ER, Aygen M, Civelek CA, Osman MM. Increased F-18 FDG Uptake in the Posterior Ocular Bulb may Indicate Brain Metastases: An initial Study. JNM, 2006; 47(1):S303.

71. Phegley DJ, Osman MM. Challenges and Solutions for Dosimetry-Guided I-131 Therapy in Patients with Thyroid Cancer: A Technologist Prospective. JNM, 2006; 47(1):S536.

72. Nguyen NC, El-Sadda W, Oliver D, Osman MM. Comparison of SUV of the Pons and Cerebellum in F-18 FDG PET/CT: Pons is a Better Internal Reference Point. JNM, 2006; 47(1):S558.

73. Osman MM, Nguyen N, Oliver D. PET/CT Characterization of Adrenal Glands in Normal Volunteers using F-18 FDG. European Journal of Nuclear Medicine and Molecular Imaging, 2006; 33(2): S263.

74. Williamson MJ, Nguyen N, Reimers HJ, Naunheim KS, Osman MM. Prevalence and Patterns of Post-Solid Organ Transplant Malignancies as Detected by F-18 FDG PET and PET/CT. European Journal of Nuclear Medicine and Molecular Imaging. 2006; 33(2):S202.

75. Nguyen N, Cooper MH, Oliver D, Reinking MF, Osman MM. Comparison of SUV of the Pons and Cerebellum in the Presence of Crossed Cerebellar Diaschisis and Anatomical Localization of Pontine Glucose Metabolic Activity with 18F-FDG-PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2006; 33(2):S289.

76. Osman MM. PET/CT Cancer Imaging in the 21st Century. Arab Health Magazine. 2007; (19): P86.

77. Sayed MM, Qubaiah OM, Oliver D, Osman MM. Added value of PET/CT in patients with cancer of unknown primary. JNM, 2007; 48(S2):377P.

78. Huston SF, Sanders V, Yost P, Osman MM. Does maintaining warmth before and during uptake definitely and non-invasively resolve FDG uptake in brown adipose tissue? JNM, 2007; 8(S2):456P.

79. Bohle R, Oliver D, Osman MM. Patterns and prevalence of mis-fusion in FDG PET/CT. JNM, 2007; 48(S2):474P.

80. Ravindra VM, Botkin CD, Yost P, Osman MM. Incidental diagnosis of prostate cancer in FDG PET/CT: An initial experience. JNM, 2007; 48(S2):474P.
81. Teymouri CH, Botkin C, Osman MM. FDG dose extravasation in PET/CT: Frequency and impact on SUV measurements. JNM, 2007; 48(S2):475P.

82. Blasé M, Botkin C, Osman MM. Comparison of 18F-FDG PET/CT and bone scan in detection of bone metastases in breast cancer. JNM, 2007; 48(S2):475P.

83. Krumrey SA, Botkin CD, Yost P, Osman MM. Prevalence of multiple cancers and detection of unexpected additional primary malignancies in patients undergoing FDG PET/CT: An initial experience. JNM, 2007; 48(S2):477P.

84. Nguyen NC, Tran I, Sayed MH, Oliver D, Williamson M, Osman MM. Combined F-18 FDG PET/CT Characterization of Talk Pleurodesis-Induced Pleural Changes: An Initial Experience. Joint Molecular Imaging Conference, Providence, Rhode Island, Abstract book, 341P, 2007.

85. Nguyen NC, Taalab K, Sayed MH, Oliver D, Williamson M, Reimers HJ, Osman MM. Combined F-18 FDG PET/CT Characterization of Cavitary Lung Lesions and Comparison of Cavitary to Non-Cavitary Lung Carcinoma. Joint Molecular Imaging Conference, Providence, Rhode Island, Abstract book, 225P, 2007.

86. Nguyen NC, Oliver D, Taalab K, Sayed MH, Williamson M, Reimers HJ, Ravindra V, Osman MM. Characterization of Indeterminate Pulmonary Nodules with F-18 FDG PET/CT: An Initial Experience. Joint Molecular Imaging Conference, Providence, Rhode Island, Abstract Book, 225P, 2007.

87. Oliver D, Varvares M, Buerck J, Osman MM, Kallogjeri D. Abstract 360 – An “in-training” Multidisciplinary Team for Customized Database Development to Disseminate Translational and Evidence Based Clinical Research. Archives of Pathology and Laboratory Medicine, October 2007.

88. Leonard K, Hunborg P, Osman MM, Hsueh EC. Abstract 247 – Utility of Breast
MRI and PET/CT Imaging in the Surgical Management of Breast Cancer Patients. Third
Annual Academic Surgical Congress, Huntington Beach, California, February 13-15,
2008.

89. Osman MM. Marginal failure to CyberKnife Stereotactic Radiosurgery as Detected with 18F FDG-PET/CT in: Preliminary Results., 7th Annual CyberKnife Users Meeting, Phoenix, Arizona, January 23-27, 2008.

90. Sayed MH, Nguyen NC, Oliver DS, Naunheim KS, Bucholz RD, Walz BJ, Osman MM. Response to Cyberknife stereotactic radiosurgery as detected with 18F FDG-PET/CT: Initial experience. JNM, 2008; 49(1):146P.

91. Moinuddin A, Hugge C, Bhatla D, Osman MM. Utilization of 18F-FDG-PET/CT in pediatric lymphoma management. JNM, 2008; 49(1):177P.

92. Nguyen NC, Nassif AS, Sayed MH, Osman MM. Characterization of brain lesions using MRI/spectroscopy versus FDG PET fused with MRI. JNM, 2008; 49(1):223P.

93. Qazi F, Oliver D, Nguyen NC, Osman MM. Fatty liver: Impact on metabolic activity as detected with 18F FDG-PET/CT. JNM, 2008; 49(1):263P.

94. Tran IT, Yost P, Oliver D, Nguyen N, Osman MM. 18F-FDG PET/CT of obese patients: Prevalence, challenges, and solutions. JNM, 2008; 49(1):415P.

95. Krumrey SA, Tran I, Yost P, Oliver D, Nguyen N, Osman MM, Qazi F. Should FDG dose be based on BMI instead of body weight? JNM, 2008; 49(1):415P.

97. Frye R, Yost P, Nguyen NC, Osman MM. Tumor-to-liver uptake ratio – Comparison of visual with semi-quantitative evaluation. JNM, 2008; 49(1):415P.

98. Bohle R, Botkin C, Oliver D, Nguyen N, Osman MM. Effects of Blood Glucose Levels on SUV. JNM, 2008; 49(1):429P.

99. Mueller T, Botkin C, Oliver D, Nguyen N, Osman MM. Prevalence of Abnormal Blood Glucose Levels in Patients Undergoing FDG PET/CT Scan. JNM, 2008; 49(1):429P.

100. March ME, Botkin C, Yost P, Nguyen N, Osman MM. 18F-FDG PET/CT for Inpatients: Prevalence and Challenges. JNM, 2008; 49(1):431P.

101. Mulugeta H, Botkin C, Yost P, Nguyen N, Osman MM. Cancellation of FDG PET scans: Patterns, Prevalence, and Financial Ramifications. JNM, 2008; 49(1):431P.

102. Lees M, Dombrowski J, Botkin C, Hubble W, Nguyen N, Osman MM. Utilization of Na22 PET markers in radiation therapy planning: Initial experience. JNM, 2008; 49(1):431P.

103. Lazoritz M, Botkin C, Oliver D, Nguyen N, Osman MM. Should MDP dose be based on body weight instead of the standard dose? Preliminary results. JNM, 2008; 49(1):433P.

104. Odell MJ, Wehrmann D, Amine M, Oliver D, Osman MM, Varvares M. Use of PET-CT as a Stand-Alone Tool for Identification of Distant Metastasis in the Initial Staging of Patients with Head and Neck Squamous Cell Carcinoma. 7th International Conference of Head and Neck Cancer, San Francisco, CA.

105. Varvares MA, Wehrmann DJ, Amine M, Oliver DS, Odell MJ, Nguyen NC, Osman MM. PET-CT in the Management of Head and Neck Malignancies: Clinical Correlation Improves Accuracy of Interpretation. 7th International Conference of Head and Neck Cancer, San Francisco, CA.

106. Nguyen NC, Farghaly HR, Powell ED, Ojile JM, Muehlbach MJ, Uhles ML, Moinuddin A, Taalab K, Osman MM. Asymmetrical Cerebral FGD Metabolism in Restless Legs Syndrome: A Novel Study During Symptomology. Sleep, 2009; 32, A308.
107. Kaushik A, Farghaly HR, Abdelmalik A, Muzaffar R, Osman MM, Nguyen NC. Oncological FDG PET/CT: Is there a universal SUV or lesion-to-liver SUV ratio? JNM, 2009; 50(2):30P.

108. Farghaly HR, Ling T, Oliver D, Walz B, Varvares M, Nguyen NC, Osman MM. Post- radiation changes in head & neck cancer patients: Patterns and prevalence as detected by 18F-FDG PET/CT. JNM, 2009; 50(2):103P.

109. Farghaly HR, Moinuddin A, Osman MM. Diagnostic role of FDG PET in dementia. JNM, 2009; 50(2):195P.

110. Farghaly HR, Moinuddin A, Kaushik A, Osman, MM. Utilization of FDG PET in evaluation of brain lesions: A pictorial essay. JNM, 2009; 50(2):106.

111. Moinuddin A, Farghaly HR, Osman MM. Utilization of FDG PET/CT by clinicians in pediatric lymphoma: Initial experience. JNM, 2009; 50(2):202P.

112. Abdelmalik A, Farghaly HR, Nguyen NC, Powell E, Ojile J, Muehlbach M, Uhles M, Osman MM. Abnormal spinal cord FDG metabolism in restless legs syndrome: A novel study during symptomology. JNM, 2009; 50(2):234P.

113. Farghaly HR, Greenwood T, Kaushik A, Frye R, Piper J, Osman MM, Abdulrauf SI, Nguyen N. Cerebral perfusion SPECT-Comparison of three different interpretation approaches. JNM, 2009; 50(2):243P.

114. Muzaffar R, Nguyen NC, Osman MM, Farghaly HR, Oliver D, Wolverson MK. Incidental diagnosis of thrombus within an aneurysm in FDG PET/CT: Frequency in 926 patients. JNM, 2009; 50(2):256P.

115. Kumar N, Kaushik A, Ruppel GL, Tran I, Farghaly HR, Osman MM, Nguyen NC. Effect of hypoxia on SUV in patients with NSCLC-Retrospective comparison between hypoxic and normoxic patients. JNM, 2009; 50(2):355P.

116. Moinuddin A, Tran I, Osman MM. Impact of respiratory gating on the metabolic activity of pulmonary lesions in FDG PET/CT: Initial experience. JNM, 2009; 50(2):372P.

117. Tran I, Moinuddin A, Krumrey S, Frye R, Yost P, Nguyen NC, Osman MM. Respiratory gating in FDG PET/CT: A technologist’s perspective. JNM, 2009; 50(2):428P.

118. Krumrey S, Frye R, Tran I, Yost P, Nguyen NC, Osman MM. FDG manual injection verses infusion system: A comparison of dose precision and extravasation. JNM, 2009; 50(2):430P.

119. Everding M, Botkin C, Hubble W, Nguyen NC, Osman MM. FDG Pet centers: The difficult balance between demands and appropriate staffing. JNM, 2009; 50(2): 443P.

120. Hosseini S, Tran I, Botkin C, Moinuddin A, Nguyen NC, Osman MM. Respiratory gating in FDG PET/CT: An initial experience. JNM, 2009; 50(2):444P.

121. Nation C, Oliver D, Botkin C, Nguyen NC, Osman MM. Impact of head holder in reducing misregistration in the area of the head and neck on PET/CT. JNM, 2009; 50(2):445P.

122. Nagel S, Botkin C, Nguyen N, Osman MM. Patterns, challenges and solutions for F-18 FDG PET/CT studies of pediatrics. JNM, 2009; 50(2):445P.

123. Bains A, Botkin C, Oliver D, Nguyen NC, Osman MM. Contamination in 18F-FDG PET/CT: An initial experience. JNM, 2009; 50(2):445P.

124. Littlejohn RC, Botkin C, Oliver D, Nguyen NC, Osman MM. Variations in arm positions in FDG PET/CT. JNM, 2009; 50(2):445P.

125. Karsch H, Muzaffar R, Botkin C, Nguyen NC, Osman MM. Incidental diagnosis of prostate cancer in FDG PET/CT: Frequency in 1420 patients. JNM, 2009; 50(2):446P.

126. Habing R, Oliver D, Botkin C, Nguyen NC, Osman MM. Patterns and prevalence of truncation artifacts in PET/CT. JNM, 2009; 50(2):446P.

127. Sahrmann J, Phegley D, Osman MM. Prevalence and challenges of pediatric studies in the nuclear medicine clinic. JNM, 2009; 50(2):442P.

128. Farghaly HR, Nguyen NC, Osman MM. Cerebral FDG PET/CT-validation of Z-scores using healthy controls from our institution. EANM-Annual Congress of the European Association of Nuclear Medicine, Barcelona, Spain, 2009.

129. Abdelmalik AG, Kaushik A, Muzaffar R, Farghaly HR, Osman MM, Nguyen NC. Update on Diagnostic Accuracy of V/Q Scan for the Diagnosis of Pulmonary Embolism. Radiological Society of North America, 2009.

130. Farghaly HR, Osman MM, Piper JW, Nelson AS, Nguyen NC. Cerebral FDG PET-correlation of asymmetry indices and differential Z-scores I healthy volunteers. Radiological Society of North America, 2009.

131. Farghaly HR, Stout J, Bucholz RR, Kaushik A, Osman MM, Nguyen NC. Seizure diagnosis using multimodality imaging of MEG, MRI, PET and SPECT. Radiological Society of North America, 2009.

132. Muzaffar R, Gonzalez EA, Moinuddin A, Oliver D, Nguyen NC, Osman MM. End Stage Renal Disease: Impact on Metabolic Activity in the Routine Internal References as Detected by 18F-FDG-PET/CT. EANM-Annual Congress of the European Association of Nuclear Medicine, Barcelona, Spain. 2009.

133. Hueser CN, Tran I, Kaushik A, Farghaly HR, Sterkel B, Osman MM, Nguyen NC. Lung Cancer staging with FDG PET/CT: Does the Veteran Affair (VA) population have unfavorable clinical features compared to non-VA population? ASTRO’s Translational Advances in Radiation Oncology and Cancer Imaging Symposium, Abstract # 15, September 11-12, 2009, St. Louis, MO.

134. Muzaffar R, Abdelmalik A, Fajnwaks P, Nguyen N, Sterkel B, Osman MM. Incidental findings in the interpretation of myocardial SPECT imaging. JNM, 2010; 51(2):175P.

135. Moinuddin A, Nguyen N, Bhatla D, Muzaffar R, Abdelmalik A, Osman MM. Benefit of true whole body FDG PET/CT imaging in pediatric Hodgkin's lymphoma. JNM, 2010; 51(2):185P.

136. Moinuddin A, Kudva G, Hurley M, Nguyen N, Osman MM. Utilization of 18F-FDG-PET/CT in cutaneous lymphoma. Society of Nuclear Medicine, Salt Lake City, Utah. JNM, 2010; 51(2):186P.

137. Moinuddin A, Nguyen N, Altinyay M, Osman MM. Detection of uncommon or isolated locations of metastatic disease by FDG PET/CT: A pictorial essay. JNM, 2010; 51(2):188P.

138. Moinuddin A, Muzaffar R, Farghaly H, Walz B, Nguyen N, Osman MM. Utilization of metabolic index in assessing Cyberknife treatment response in patients with stage 1a non small cell lung cancer. JNM, 2010; 51(2):230-231P.

139. Moinuddin A, Farghaly H, Muzaffar R, Reimers H, Zoghbi C, Nguyen N, Osman MM. Utilization of FDG PET/CT in assessing gastrointestinal metastatic disease from lung cancer. JNM, 2010; 51(2):231P.

140. Farghaly H, Abdelmalik A, Piper J, Nelson A, Osman MM, Nguyen N. Cerebral FDG PET - Comparison of Z-scores between single brain atlas and probalistic atlas. JNM, 2010; 51(2):242P.

141. Altinyay M, Touma W, Oliver D, Abdelmalik A, Muzaffar R, Nguyen N, Osman MM. Metabolic characterization of untreated lung adenocarcinoma with 18F-FDG PET/CT: Impact of smoking. JNM, 2010; 51(2):330P.

142. Muzaffar R, Osman MM, Abdelmalik A, Fajnwaks P, Nguyen N. Protective value of intramural thrombus in the abdominal aortic aneurysm: Metabolic changes as detected by FDG PET/CT. JNM, 2010; 51(2):364P.

143. Lang A, Botkin C, Hubble W, Osman MM. Administration of iodinated contrast media by nuclear medicine technologists: Awareness and training. JNM, 2010; 51(2):407P.

144. Kistner B, Botkin C, Hubble W, Osman MM. Proposed reduction in whole body maximum permissible dose for occupational workers: Awareness and potential impact. JNM, 2010; 51(2):407P.

145. Moore T, Oliver D, Botkin C, Abdelmalik A, Nguyen N, Osman MM. Incidental brain findings detected on F-18 FDG PET/CT images of patients evaluated for body malignancies. JNM, 2010; 51(2):411-412P.

146. Croxford A, Fajnwaks P, Botkin C, Oliver D, Nguyen N, Osman MM. Prevalence and patterns of metal artifacts in FDG PET/CT. JNM, 2010; 51(2):412P.

147. Bouckaert K, Oliver D, Hubble W, Botkin C, Nguyen N, Osman MM. Impact of chemotherapy on liver SUV in F-18 FDG PET/CT. JNM, 2010; 51(2):413P.

148. Groh E, Botkin C, Oliver D, Osman MM. Liver SUV in whole body 18F FDG-PET/CT: Stability and correlation with age and gender. JNM, 2010; 51(2):413P.

149. Collier T, Oliver D, Botkin C, Nguyen N, Osman MM. Should liver SUV still be used as an internal reference in the presence of benign liver diseases? JNM, 2010; 51(2):413P.

150. Crandall S, Muzaffar R, Hubble W, Botkin C, Phegley D, Nguyen N, Osman MM. A technologist perspective on half-time myocardial perfusion imaging: A promising new technology. JNM, 2010; 51(2):414P.

151. Kalthoff A, Hubble W, Botkin C, Littlefield J, Osman MM. Availability and utilization of pinhole collimators in modern nuclear medicine departments: An update. JNM, 2010; 51(2):415P.

152. Hurtgen K, Yost P, Tran I, Krumrey S, Oliver D, Nguyen N, Osman MM. Oral Hypoglycemics on 18F-FDG Bowel Uptake: A Technologist Perspective. JNM, 2010; 51(2):393P.

153. Muzaffar R, Oliver D, Abdelmalik A, Fajnwaks P, Nguyen N, Osman MM. Half-time cardiac imaging acquisition- A comparative study. European Association of Nuclear Medicine annual meeting, October 2010.

154. Nguyen NC, Abdelmalik A, Osman MM, Geller TJ. Does periventricular white matter hyperintensities as seen on MRI images effect cerebral glucose metabolism? A retrospective study. Eur J Nucl Med Mol Imaging, 2010, 37(2):P320.

155. Abdelmalik AG, Muzaffar R, Nguyen NC, Osman MM. The incremental added value of including the head in F18-FDG PET/CT imaging for cancer patients. European Association of Nuclear Medicine annual meeting, October 2010.

156. Nguyen NC, Abdelmalik A, Osman MM, Geller TJ. Cognitive impairments in pediatric patients with Neurofibromatosis type 1 correlated with FDG PET – a retrospective series. Eur J Nucl Med Mol Imaging, 2010; 37(2):P299.

157. Almardoof A, Altinyay ME, Touma W, Nguyen NC, Osman MM. Liver and mediastinum SUV in F-18 FDG PET/CT: Impact of immunotherapy. JNM, 2011; 52(1):177P.

158. Fajnwaks P, Altinyay ME, Muzaffar R, Nguyen NC, Osman MM. Benign incidental CT findings and corresponding metabolic changes in FDG PET/CT: A pictorial essay. JNM, 2011; 52(1):184P.

159. Fajnwaks P, Abdelmalik A, Muzaffar R, Osman MM, Nguyen NC. Demonstration of active osteoarthropathy at In-111 Zevalin scan in a patient with non-Hodgkin’s lymphoma. JNM, 2011; 52(1):196P.

160. Abdelmalik A, Almardoof A, Osman MM, Nguyen NC. The prevalence of abnormal joint uptake in the lower extremities on 18F-FDG PET/CT in relation to patient’s age and BMI. JNM, 2011; 52(1):283P.

161. Almardoof A, Altinyay ME, Yost PE, Osman MM, Nguyen NC. FDG dose reduction in pediatric oncology correlated with EANM procedure guidelines-A case series. JNM, 2011; 52(1):286P.

162. Muzaffar R, Altinyay ME, Sarajlic L, Weaver O, Snell S, Doherty CM, Nguyen NC, Osman MM. Incidental diagnosis of breast cancer in FDG PET/CT: Frequency in 1283 patients. JNM, 2011; 52(1):403P.

163. A Lang, Osman MM, Botkin C, Hubble WL. The usefulness of ventilation/perfusion scans in children with pulmonary artery stenosis. JNM, 2011; 52(1):507P.

164. Schmitt C, Hoth EL, Botkin C, Hubble WL, Osman MM. SPECT/CT: A comparison of initial expectations versus actual utilization. JNM, 2011; 52(1):508P.

165. Turnadzic A, Botkin C, Hubble WL, Osman MM. Same day appointments after PET/CT: A potential radiation exposure to medical personnel and general public. JNM, 2011; 52(1):511P.

166. Valdez K, Botkin C, Hubble WL, Littlefield JL, Osman MM. A single institution study comparing radiation exposure: MPI versus CCTA. JNM, 2011; 52(1):512P.

167. Kistner B, Botkin C, Hubble WL, Touma W, Osman MM. Patterns of myocardial uptake in FDG-PET/CT scans: Impact of changes in left ventricular ejection fraction. JNM, 2011; 52(1):513P.

168. Yan T, Botkin C, Hubble WL, Osman MM. Does weight loss affect stability of liver SUV in patients with head and neck cancer? JNM, 2011; 52(1):514P.

169. Kalthoff AM, Hubble WL, Botkin C, Hoth EL, Smith RW, Osman MM. Patient exposure and diagnostic quality: An analysis of solid-state semiconductor technology in myocardial perfusion imaging. JNM, 2011; 52(1):516P.

170. Al-Mardoof AO, Abdelmalik A, Osman MM, Nguyen NC. Characterization of extra-axial brain lesions using MRI versus co-registered FDG PET. Presented at the European Association of Nuclear Medicine annual meeting, October, 2011.

171. Abdelmalik A, Sarajlic L, Muzaffar R, Osman MM. Pituitary adenoma: Incidentaloma identified by F18-FDG PET/CT. JNM, 2012; 53(1):30P.

172. Hemstock T, Botkin C, Hubble W, Osman MM, Nguyen N. 123 I-Ioflupane: A new and promising tracer for Parkinson’s disease. JNM, 2012; 53(1):613P.

173. Krawiecki R, Botkin C, Hubble W, Muzaffar R, Osman MM. Added benefits of SPECT/CT in non-malignant nuclear medicine studies. JNM, 2012; 53(1):613P.
174. Simpson N, Botkin C, Hubble W, Hurtgen K, Muzaffar R, Osman MM. Added value of SPECT/CT in cancer imaging. JNM, 2012; 53(1):614P.

175. Sarajlic L, Botkin C, Hubble W, Abdelmalik A, Osman MM. The incremental added value of including the head in the imaged field of view: A retrospective evaluation of 8431 18F-FDG PET/CT studies. JNM, 2012; 53(1):616P.

176. Hammann K, Bicklein S, Botkin C, Hubble W, Dombrowski J, Abdelmalik A, Osman MM. Role of FDG PET/CT in prediction of post-radiation therapy chest wall toxicity. JNM, 2012; 53(1):617P.

177. Watson E, Botkin C, Hubble W, Schmidt M, Wadford J, Osman MM. Vendor reported CTDI vs. actual CTDI in SPECT/CT: Initial experience. JNM, 2012; 53(1):618P.

178. Muzaffar R, Fajnwaks P, Sarajlic L, Abdelmalik A, Osman MM. Pictorial essay: Ophthalmologic abnormalities in FDG PET/CT. JNM, 2012; 53(1):200P.

179. Touma W, Fajnwaks P, Muzaffar R, Parkar N, Osman MM. Does FDG PET/CT distinguish malignant from benign pleural effusions in patients with lung cancer? An initial experience. JNM, 2012; 53(1):294P.

180. Nyon S, Abhishek K, Abdelmalik A, Osman MM, Nguyen N. Is the prognosis different between lung cancer with and without cavitary feature? A retrospective FDG PET/CT study. JNM, 2012; 53(1):294P

181. Stout J, Yang G, Osman MM, Michael AP, Mogul D, Roskos P, Feller JG, Bucholz RD. Surfacebased analysis of positron emission tomography data in mild to moderate blast induced
traumatic brain injury. Neuroscience 2012 (New Orleans, Oct 13-17, 2012).

182. Gandhi H, Hewing D, Botkin K, Hubble W, Turner J, Osman MM. Amyvid: A review and assessment of clinical implementation. Presented at the 60th Annual Society of Nuclear Medicine and Molecular Imaging Meeting, Vancouver, British Columbia, Canada, June 2013.

183. Sarajlic L, Botkin K, Hubble W, Hewing D, Turner J, Osman MM. I-131 Therapy: Lack of adherence to NRC and SNM guidelines regarding potential radiation exposure to the unborn. Presented at the 60th Annual Society of Nuclear Medicine and Molecular Imaging Meeting, Vancouver, British Columbia, Canada, June 2013.
184. Yoder K, Hewing D, Botkin C, Hubble W, Turner J, Osman MM. Development and validation of simple methods to reduce radiation exposure from FDG PET/CT patients. Presented at the 60th Annual Society of Nuclear Medicine and Molecular Imaging Meeting, Vancouver, British Columbia, Canada, June 2013.

185. Helina D, Botkin C, Hubble W, Hewing D, Turner J, Osman MM. Comparison of radiation doses for 18-F FDG PET/CT imaging and the effect of varying protocols on image interpretation. Presented at the 60th Annual Society of Nuclear Medicine and Molecular Imaging Meeting, Vancouver, British Columbia, Canada, June 2013.

186. Kirchgesner C, Botkin C, Hubble W, Hewing D, Turner J, Osman MM. The variability of CT techniques and radiopharmaceutical doses for SPECT/CT MPI studies. Presented at the 60th Annual Society of Nuclear Medicine and Molecular Imaging Meeting, Vancouver, British Columbia, Canada, June 2013.

187. Young E, Kennedy M, Turner J, Hubble W, Hewing D, Osman MM. PET/MR: We Can Merge Technology, but Can We Merge Technologists? Presented at the 60th Annual Society of Nuclear Medicine and Molecular Imaging Meeting, Vancouver, British Columbia, Canada, June 2013.

188. Raslan O, Zhou Y, Varvares M, Osman MM. Accuracy of 18F-FDG PET/CT in assessing direct osseous invasion by head & neck tumors: A Pathological correlation. Annual Congress of the European Association of Nuclear Medicine, Lyon, France, October 19 - 23, 2013.

189. Osman MM, Muzaffar R, Roskos P, Malone T, Bucholz R. Utilization of 18F-FDG PET/CT to differentiate PTSD from TBI and the relationship of the hypothalamic-pituitary axis: initial experience. Annual Congress of the European Association of Nuclear Medicine, Lyon, France, October 19 - 23, 2013.

190. Farmakis S, Vejdani K, Muzaffar R, Parkar N, Osman MM. The forgotten cardiophrenic lymph node: Its role in staging and management as detected by FDG PET/CT. Annual Congress of the European Association of Nuclear Medicine, Lyon, France, October 19 - 23, 2013.

191. Rahman A, Muzaffar R, Sarajlic L, Osman MM. Incidental finding of increased uptake in the lateral pterygoid muscle in FDG PET/CT: frequency in 1017 patients. Annual Congress of the European Association of Nuclear Medicine, Lyon, France, October 19 - 23, 2013.

192. Muzaffar R, Sarajlic L, El-Gammal Y, Owen J, Osman MM. Incidental diagnosis of plantar fibromatosis in FDG PET/CT: frequency in 1751 patients. Annual Congress of the European Association of Nuclear Medicine, Lyon, France, October 19 - 23, 2013.

193. Osman MM, Muzaffar R, Roskos P, Malone T, Bucholz R. Identifying the relationship between the hypothalamic-pituitary axis: initial experience. Annual Congress of the European Association of Nuclear Medicine, Lyon, France, October 19 - 23, 2013.

194. Farmakis S, Vejdani K, Muzaffar R, Parkar N, Osman MM. The forgotten cariophrenic lymph node: Its role in staging and management as detected by FDG PET/CT. Annual Congress of the European Association of Nuclear Medicine, Lyon, France, October 19 - 23, 2013.

195. Stout J, Bolzenius J, Roskos T, Osman MM, Frausto R, Bucholz R, Mogul D. fMRI Assessment of Load Based Working Memory in Blast TBI and Associated Effect in FDG-PET Signal. Neural Engineering Conference, November 6, 2013.

196. Laughhunn L, Botkin C, Hubble W, Hewing D, Turner J, Muzaffar R, Robertson E, and Osman MM. Xofigo: An exciting new therapy for prostate cancer. Society of Nuclear Medicine annual meeting, St. Louis, MO, June, 2014.

197. Green A, Van Alstine C, Tetri B, and Osman MM. Brown fat detected by FDG PET/CT is protective against features of the metabolic syndrome. Society of Nuclear Medicine annual meeting, St. Louis, MO, June, 2014.

198. Drakopoulos M, Vejdani K, and Osman MM. Comparison of diagnostic certainty and accuracy of 18F-NaF PET/CT and planar 99mTc-MDP bone scan in patients with prostate cancer. Society of Nuclear Medicine annual meeting, St. Louis, MO, June, 2014.

199. Raslan O, Sarajlic L, Romney J, Vejdani K, and Osman MM. Diagnostic accuracy of 18F-FDG-PET/CT, contrast enhanced MRI and diffusion weighted MRI in the differentiating brain tumor recurrence from radiation necrosis. Society of Nuclear Medicine annual meeting, St. Louis, MO, June, 2014.

200. Raslan O, Allam T, Kujawa K, Brock K, Muzaffar R, Shetty V, Varvares M, and Osman MM. Effectiveness of 18 F-FDG PET/CT in detecting cranial nerve pathology. Society of Nuclear Medicine annual meeting, St. Louis, MO, June, 2014.

201. Raslan O, Muzaffar R, Vejdani K, and Osman MM. Tumor imaging of the head and neck in 18F-FDG PET/CT: Anatomy and patterns of disease spread. Society of Nuclear Medicine annual meeting, St. Louis, MO, June, 2014.

202. Raslan O, Marko A, Sona K, Daugherty E, Kujawa K, Varvares M, and Osman MM. The value of 18F-FDG-PET/CT in detection of lesions below the diaphragm in patients with head and neck cancer. Society of Nuclear Medicine annual meeting, St. Louis, MO, June, 2014.

203. Sarajlic L, Raslan O, Hewing D, Vejdani K, and Osman MM. The value of SUVmax in the differentiation of high-grade from low-grade primary brain tumors and primary brain tumors from metastatic lesions. Society of Nuclear Medicine annual meeting, St. Louis, MO, June, 2014.

204. Vejdani K, Gandhi H, Hewing D, Muzaffar R, Osman MM, and Chand P. Effect of CT attenuation correction on striatal 123I-ioflupane uptake evaluation: A quantitative comparison using brain SPECT and SPECT/CT images. Society of Nuclear Medicine annual meeting, St. Louis, MO, June, 2014.

205. Romney J, Hewing D, Osman MM, and Raslan O. Evaluating imaging differences between PET/CT and various MR imaging methods in patients with brain tumors. Society of Nuclear Medicine annual meeting, St. Louis, MO, June, 2014.

206. Sona K, Hewing D, Turner J, Raslan O, and Osman MM. PET/MR hybrid imaging: The new gold standard in radiotherapy planning of squamous cell head and neck cancer? Society of Nuclear Medicine annual meeting, St. Louis, MO, June, 2014.

207. Havrilla A, Raslan O, Hurtgen K, Botkin C, Hubble W, Hewing D, Sayed M, and Osman MM. Value of Tc-99m-bicisate (ECD) balloon test occlusion in preoperative assessment of stroke risk prior to internal carotid artery sacrifice. Society of Nuclear Medicine annual meeting, St. Louis, MO, June, 2014.

208. Lammert M, Hewing D, Kennedy M, Turner J, Muzaffar R, and Osman MM. A mouse to a moose: The emerging world of veterinary radiology. Society of Nuclear Medicine annual meeting, St. Louis, MO, June, 2014.

209. Wendorf C, Botkin C, Hubble W, Hewing D, Groh E, Muzaffar R, and Osman MM. Investigating ways to address the Joint Commission’s new diagnostic imaging standards in reference to radiation dose tracking. Society of Nuclear Medicine annual meeting, St. Louis, MO, June, 2014.

210. Wahidi J, Hubble W, Hewing D, Botkin C, and Osman MM. Y-90 Sir-Sphere treatment of liver cancer and alternative imaging methods. Society of Nuclear Medicine annual meeting, St. Louis, MO, June, 2014.

211. Daugherty E, Raslan O, Bicklein S, Kienstra K, Hewing D, and Osman MM. 18F-FDG-PET/CT in assessment of post radiation changes in patients with head and neck squamous cell carcinoma. Society of Nuclear Medicine annual meeting, St. Louis, MO, June, 2014.

212. Van Alstine C, Green A, Botkin C, Hewing D, Hubble W, and Osman MM. Brown fat detected by FDG PET/CT is protective against elevated fasting blood glucose in obese patients. Society of Nuclear Medicine annual meeting, St. Louis, MO, June, 2014.

213. Sweet H, Vejdani K, Muzaffar R, Hewing D, Botkin C, Hubble W, and Osman MM. Inter-reader reliability among regions of interest in 123I-ioflupane (DaTscan) brain SPECT image processing. Society of Nuclear Medicine annual meeting, St. Louis, MO, June, 2014.

214. Marko A, Raslan O, Bicklein S, Kienstra K, Hewing D, and Osman MM. Value of 18F-FDG PET/CT in detection of malignant lesions outside the head and neck region in patients with head and neck cancer. Society of Nuclear Medicine annual meeting, St. Louis, MO, June, 2014.

215. Raslan O, Allam T, Shetty V and Osman, MM. (18) F-FDG-PET/CT of Cranial Nerve Pathology. Digital Poster, Accepted for presentation at Radiological Society of North America (RSNA) meeting; Chicago, IL, USA, 2014.

216. Vejdani K, Chand P, Muzaffar R, Osman MM. Clinical correlation of 123I-ioflupane brain SPECT with symptom severity, chronicity and laterality in the assessment of Parkinsonian movement disorders. EANM'14 - Annual Congress of the European Association of Nuclear Medicine (October 18 - 22, 2014 in Gothenburg/Sweden).

217. Vejdani K, Chand P, Muzaffar R, Osman MM. Technical considerations of image acquisition and processing in quantitative 123I-ioflupane brain SPECT. EANM'14 - Annual Congress of the European Association of Nuclear Medicine (October 18 - 22, 2014 in Gothenburg/Sweden).

218. Marko A, Muzaffar R, Bicklein S, Kienstra K, Osman MM. Evaluation of pregnancy screening procedures prior to Iodine-131 treatment in postmenopausal women with thyroid disease.

219. Yasin J, Mikhayel M, Parkar N, Muzaffar R, Botkin C, Hubble WL, Osman MM. The effect of pulmonary arterial hypertension on Standardized Uptake Values (SUV) of the liver in PET/CT imaging.

220. Fohne L, Ahmed F, Botkin C, Hubble WL, Osman MM. Identification of bone lesions on PET/CT imaging: A comparison of PET to CT detection capabilities.

221. Daniel NP, Ahmed F, Bicklein S, Kienstra K, Muzaffar R, Osman MM. Value of PET/CT in assessing post-radiotherapy changes in bone metastases.

222. Gharabagi AC, Hubble WL, Botkin C, Ahmed M, Muzaffar R, Osman MM. Assessing Liver Standard Uptake Value (SUV) in Patients with Congestive Heart Failure (CHF) versus those without CHF using Positron Emission Tomography (PET) as an Imaging Modality

223. Sweet H, Parkar N, Hewing DL, Osman MM, Muzaffar R. The Validity of Using Low Dose CT from FDG PET/CT Scans to Obtain Calcium Scores and Determine Patient Treatment

224. Ahmed F, Fohne L, Muzaffar R, Kelly P, Fernandes H, Tu Y, Osman MM. Bone metastasis as detected by FDG PET with negative CT of the PET/CT: Frequency in 2000 scans.

225. Bagci, U, Papadakis G, Xu Z, Green A, Osman MM, Shah M. Nuclear Medicine Meets Computer Vision: Increasing Role of Computerized Detection, Tracking, Diagnosis, and Quantification of PET/CT and PET/MRI Studies. JNM, 2015; 56: 1922

226. Green A, Bagci U, Kelly P, Osman MM. Brown Adipose Tissue Detected by FDG PET/CT is Associated with Less Central Abdominal Visceral Fat. JNM, 2015; 56: 1416.

227. Green A, Bagci U, Kelly P, Osman MM. Brown Adipose Tissue May Be Associated With a Lower Ratio of Abdominal Obesity to Whole Body Obesity Compared to Body Mass Index Matched Controls. JNM, 2015; 56: 1654.

228. Green A, Van Alstine C, Kelly P, Neuschwander-Tetri B, Osman MM. Brown Fat Detected by FDG PET/CT is Protective Against Features of the Metabolic Syndrome. JNM, 2014; 55:1645

229. Ahmed M, Muzaffar R, Osman MM. The potential impact of congestive heart failure (CHF) on FDG PET/CT studies. Accepted for the European Association of Nuclear Medicine (EANM) Congress 2015

230. Mikhayel M, Parkar N, Muzaffar R, Osman MM. The Effect of Pulmonary Hypertension on Standardized Uptake Values of the Liver and Pulmonary artery in FDG PET/CT Imaging. Accepted for the European Association of Nuclear Medicine (EANM) congress 2015

231. Spiegel B, Hubble W, Botkin C, Osman MM, “Identifying the Role Technologists May Play in Meeting Compliance with the PET PROS Elements of PET/CT Reporting Guidelines.” Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging, San Diego, CA, June 2016

232. Mustain E, Botkin C, Hubble W, Osman MM, “Sentinel Lymph Node Detection in Melanoma Patients; Impact of Lesion Location, Patient's Age, Gender, Weight and CHF.” Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging, San Diego, CA, June 2016

233. Lasmett H, Daniel N, Ahmed F, Hewing D, Muzaffar R, Osman MM, “Pattern and prevalence of sinus disease as detected with FDG PET/CT.” Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging, San Diego, CA, June 2016

234. Karsch H, Hewing D, Kelly P, Muzaffar R, Osman MM. “Impact of renal failure on F18- FDG PET/CT scans.” Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging, San Diego, CA, June 2016

235. Daniel N, Lashmett H, Hewing D, Albalooshi B, Muzaffar R, Osman MM, “Thyroid Incidentalomas detected on PET/CT scans: Frequency in 1,438 patients.” Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging, San Diego, CA, June 2016

236. Bauer K, Lathrum A, Raslan O, Hewing D, Kelly PV, Zhou Y, Osman MM, “Does gadolinium-based contrast agents affect the 18F-FDG PET/CT uptake in the dentate nucleus and the globus pallidus? A pilot study.” Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging, San Diego, CA, June 2016

237. Lathrum A, Raslan O, Hewing D, Kelly PV, Zhou Y, Osman MM, “Is T1-Weighted Fluid-Attenuated Inversion Recovery sequence A Viable Alternative for T1-Weighted Spin Echo Imaging In assessment of Gadolinium based Contrast Material deposition in the Brain?” Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging, San Diego, CA, June 2016

238. Fohne L, Raslan O, Hewing D, Osman MM, “Utilization of the Unenhanced CT of PET/CT to assess serial calcium scoring in lymphoma patients.” Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging, San Diego, CA, June 2016

239. El-Sabbagh A, Muzaffar R, Osman MM. “Chemotherapy-Induced Coronary Calcium Score Deterioration in Lymphoma Patients as Detected with Unenhanced CT Portion of FDG EPT/CT.” Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging, San Diego, CA, June 2016

240. Ahmed F, Muzaffar R, Osman MM. “Non-oncologic FDG Avid Incidental Findings in the Lower Extremities in 18F-FDG PET/CT,” Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging, San Diego, CA, June 2016

241. Bakdalieh A, Zawin J, Muzaffar R, Osman MM. “Clinically Significant Incidental Findings on the Unenhanced CT Portion of Pediatric FDG-PET/CT Studies: Frequency in 410 Cases,” Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging, San Diego, CA, June 2016

242. Osman, MM, Iravani A, Hicks R, Hofman M. “Detection of Unexpected Additional Primary Malignancies with 68Ga-PSMA PET/CT in Patients with Prostate Cancer: Frequency in 765 Patients,” J Nucl Med, 2017; 58:736.

243. Osman MM, Iravani A, Hofman M, Hicks R. “Physiologic 68Ga-PSMA PET/CT Uptake in Ganglia: A Potential Pitfall in Staging and Restaging Patients with Prostate Cancer.” J Nucl Med, 2017; 58:978.

244. Osman MM, Iravani A, Hofman M, Hicks, R. “Role of 68Ga-PSMA PET/CT as a Confirmatory Test in Asymptomatic Men with Abnormal Circulating Tumor Cells expressing Androgen Receptor and Prostate Specific Antigen; Preliminary Data.” J Nucl Med, 2017; 58:1084.

245. Ahmed F, El-Sabbagh A, Muzaffar R, Osman M. Lipomatous hypertrophy of the inter-atrial septum: FDG PET/CT appearance and clinical correlation, J Nucl Med, 2017; 58:964.

246. Frye R, Frye S, Osman M. A photopenic circular artifact that resulted in a gamma camera head rebuild: A technologist case study. J Nucl Med, 2017; 58:792.

247. Hristov H, Hedgepeth B, Frye S, Hubble W, Botkin C, Lee H, Zhou Y, Muzaffar R, Osman M. Patterns and prevalence of F18-FDG uptake on Pet/CT in conus medullaris and comparison with contrast-enhanced lumbar MRI in the same patient. J Nucl Med, 2017; 58:1151.

248. Osman M, Townsend D, Frye S, Lattanze R, Muzaffar R. Prolonged Venous Stasis: Invisible Intravenous FDG Infiltrations and Potential Negative Implications in PET/CT Examination. J Nucl Med, 2017; 58:669.

249. Bakdalieh A, Osman M, Muzaffar R, Ghazala H, Zhou Y. Crossed cerebellar diaschisis on F-18 FDG PET/CT and MRI-Functional MRI. J Nucl Med, 2017, 58:1259.

250. Ryan A, El-Sabbagh A, Frye S, Hubble W, Botkin C, Osman M. Differences between HPV-positive and HPV-negative head and neck cancer patients as detected with FDG F18 PET/CT. J Nucl Med, 2017; 58:831.

251. Osman MM, Koester E, McMunn A, Muzaffar R. Development and Validation of Simple Methods to Reduce Radiation Exposure to Public from FDG PET/CT Patients. EANM'17 - Annual Congress of the European Association of Nuclear Medicine (October 21 - 25, 2017 in Vienna/Austria).

252. Assiri Z, El-Sabbagh A, Muzaffar R, Osman MM. Morphologic and Metabolic differences between HPV-positive and HPV-negative Oropharyngeal cancer patients as detected with FDG F18 PET/CT. EANM'17 - Annual Congress of the European Association of Nuclear Medicine (October 21 - 25, 2017 in Vienna/Austria).

INVITED LECTURES AND CME PROGRAMS:

Local/Regional:

Jan. 2003 Tumor Board, DePaul Hospital, St. Louis, MO. “The Role of PET and PET/CT in Oncology.”

Jun 2003 Forest Park Hospital, St. Louis, MO. “The Role of PET and PET/CT in Oncology”.

Jul 2003 Medical Staff Meeting, Forest Park Hospital, St. Louis, MO. “The Role of PET and PET/CT in Oncology”

Oct 2003 Ozark Chest Conference XXIII, Missouri Thoracic Society. “Staging of Non-Small Cell Lung Cancer with Integrated PET/CT Scanning”.

Christian Hospital, BJC Health Care, St. Louis, MO “PET/CT: The Future of Nuclear Medicine”

17th Annual Fall Cancer Symposium. Southeast Missouri Hospital Regional Cancer Center. Cape Girardeau, MO. “Role of PET and PET/CT Imaging in Oncology”

Feb 2004 Mexico, MO. “Oncologic Applications of PET/CT”.

Apr 2004 Grand Rounds, Alton Memorial Hospital. Alton, IL. “Oncologic Applications of PET/CT”.

Oct 2005 Society of Nuclear Medicine, Missouri Valley Chapter Annual Meeting. “PET/CT; Thinking outside the box”.

Apr 2005 Advances in Hybrid Imaging, Marysville, MO. “The Clinical Value of PET/CT”.

Sep 2005 Community Brain Tumor Conference, St. Louis, MO. “PET/CT Metabolic Imaging of Brain Tumors”.

Oct 2005 The 22nd Annual Medical Symposium in the Ozarks. MO. “PET Scan”.

Dec 2005 Grand Rounds, Ottawa Hospital. Ottawa, IL. “Oncologic Applications of PET/CT”.

Feb 2006 Grand Rounds, Sparta Hospital. Sparta, IL. “PET/CT in Oncology”.

Oct 2006 Science Frontiers, Academy of Science, Science Center, St. Louis, MO. “PET/CT in Oncology: Thinking outside the box”.

Apr 2008 DePaul Hospital, St. Louis, Missouri. “How to Incorporate FDG PET/CT Into Your Clinical Practice”

Oct 2009 Missouri Valley Chapter, Society of Nuclear Medicine annual meeting, Kansas City, MO. “Imaging with the Experts”

Oct 2010 Missouri Valley Chapter, Society of Nuclear Medicine annual meeting, St. Louis, MO. “Imaging with the Experts”

Oct 2011 Missouri Valley Chapter, Society of Nuclear Medicine annual meeting, Lake Ozark, MO. “Imaging with the Experts”

Oct 2013 Missouri Valley Chapter of the SNMMI 34th annual meeting, Omaha, Nebraska.
“Head and Neck Anatomy with PET/ CT Correlation”
“Read with the experts:

April 2015 SSM Health Care (Part of the 2015 Spring Cancer Lecture Series) "How to read and report PET/CT"

Aug 2015 International Atomic Energy Agency/Saint Louis University Scientific Course, St. Louis, MO

Dec 2015 Cardinal Glennon Children’s Hospital Grand Rounds, “Radiation Doses in Nuclear Medicine”

Sept 2016 Missouri Valley Chapter of the SNMMI, Lake Ozarks, MO
“Radiation Doses To and From Patients in Nuclear Medicine: Challenges and Solutions”

Feb 2017 St. Louis Society of Internal Medicine, St. Louis, MO
“Theranostics: The Future of Nuclear Medicine”

April 2017 Doisy College of Health Sciences Scholarship Committee Colloquium, Saint Louis University, St. Louis, MO
“The MIRT Research Initiative: Bridging Student and Clinical Research”

National:

Sept. 2002 American Society of Nuclear Cardiology, 7th Annual Symposium and Scientific Session, Baltimore, MD. “Hybrid PET Cameras, PET/CT Imaging in Oncology; What Did We Learn?

Feb. 2003 Grand Rounds, Lawrence Memorial Hospital, Kansas City, MO. “The Role of PET in Oncology”

April 2003 The Eastern Iowa Subchapter of the SNM, Moline, IL. “Radioimmunotherapy in Non-Hodgkins Lymphoma”.

Surgical Grand Rounds, Westchester University Hospital, Westchester, NY. “Role of PET and PET/CT in Oncology”.

Grand Round, Sound Shore Medical Center, New Rochelle, NY. “Role of PET and PET/CT in Oncology”.

May 2003 Tumor Board, Methodist Hospital, Omaha, NE. “Oncologic Applications of PET”.
Nebraska Health Imaging, Omaha, NE. “The Art of PET”.

July 2003 University PET/CT Imaging, PC, Westchester Medical Center, Westchester, NY. “Role of PET and PET/CT in Oncology”.

Sept. 2003 PET Imaging 2003, Las Vegas, Nevada” PET and PET/CT in Oncology: What the Oncologist Wants From the PET Provider”

Jan. 2004 Saint Barnabas Medical Center, Livingston, New Jersey. “Oncologic applications of PET”

June 2004 Society of Nuclear Medicine 51st Annual Meeting, Philadelphia, PA. “GEMINI 16 Power PET/CT”

July 2004 Society of Nuclear Medicine PET Learning Center. “PET and PET/CT: Physics, Instrumentation and Applications”, Arlington, VA.

Jan. 2005 University of Alabama. Head and Neck Tumor Conference, UAB, Birmingham, Alabama. “Oncologic Applications of PET/CT in Head and Neck Cancer”

April 2005 Medical Staff Meeting, Memorial Health System, Lufkin, TX. “PET/CT: Effective Use to Maximize Patient Benefit”
Medical Staff Meeting, St. Francis Hospital, Columbus, GA “Oncologic Applications of PET/CT”

Sep 2005 Houston, Texas. “PET/CT: Effective Use to Maximize Patient Benefit”

Feb 2006 Denver, Colorado. “Cost Effectiveness of PET/CT”

May 2006 El Paso, Texas. “PET/CT: Past, Present, and Future”

Jan 2008 Scottsdale, Arizona. 7th Annual CyberKnife Users Meeting

April 2008 South Bend, IN, Memorial Hospital, PET Scanning in the Community: Indications for a Mysterious Test

June 2008 Ft. Lauderdale, Florida. Philips Oncology Symposium, “The Value of PET/CT Imaging in Cancer Diagnosis, Staging, Restaging and Surveillance”

June 2008 Detroit, MI. Active Communications International 10th National Conference on Adding, Updating, & Expanding Comprehensive Cancer Programs & Services, “PET/CT Imaging in Cancer Diagnosis, Staging, Restaging, and Surveillance”

Aug 2008 Anaheim, California. PET/CT – Nuclear Medicine Update for Technologists “Oncologic Applications for PET/CT”
“Technical Challenge & Solutions for Acquiring PET/CT Studies in a Busy PET Center”

Oct 2008 Omaha, Nebraska. Society of Nuclear Medicine, Missouri Valley Chapter – “Imaging with the Experts”

Madisonville, KY. “Added Value of 18F-FDG PET/CT in Oncology”

Las Vegas, Nevada. Sixth annual Practical PET Imaging 2008: A Focus on PET and PET/CT

Feb 2009 Clearwater Beach, Florida. – Philips Healthcare SPECT/CT Symposium, “Why SPECT/CT in Nuclear Medicine?”

Chicago, Illinois. Philips Healthcare SPECT/CT Symposium, “Why SPECT/CT in Nuclear Medicine?”

Seattle, Washington. Philips Healthcare SPECT/CT Symposium, “Why SPECT/CT in Nuclear Medicine?”

Dallas, TX. Philips Healthcare SPECT/CT Symposium, “Why SPECT/CT in Nuclear Medicine?”

May 2009 Kearney, Nebraska. Good Samaritan Healthy Systems, Noon Conference: Positron Emission Tomography

July 2009 San Antonio, Texas. South Texas Radiology Group: “Added Value of PET/CT in Oncology: The SLU Experience”

Oct 2009 Wichita, KS, Salina Regional Health Center, Time of Flight PET System

Sept 2010 Blue Cross/Blue Shield, Dallas, TX. “PET Coverage”
Oct 2010 Las Vegas, NV. Educational Symposia: “Added Value of True Whole Body in FDG-PET” and “FDG PET-CT Reporting Guidelines”

June 2011 San Antonio, Texas. Society of Nuclear Medicine annual meeting; “Updates in PET/CT in Oncology”

Sept 2011 Baltimore, Maryland. American Society of Nuclear Cardiology; “Updates in PET/CT and SPECT/CT”

Oct 2012 Las Vegas, Nevada, Educational Symposia: 10th annual Practical PET Imaging, A Focus on PET & PET-CT; “Added Value of True Whole Body in FDG PET-CT,” “Imaging Pitfalls and Artifacts,” “Unexpected Sites of Malignancy as Detected with FDG PET-CT,” and “Interesting Case Challenge”

Feb 2013 Sentara Heart Hospital, Norfolk, VA “Nuclear Cardiology SPECT and PET 2013 Updates”

June 2014 St. Louis, Missouri, Society of Nuclear Medicine and Molecular Imaging 61st annual meeting
“PET Imaging of Sarcomas”

Oct 2015 Missouri Valley Chapter, Society of Nuclear Medicine & Molecular Imaging 36th annual meeting, St. Louis, MO
“Radiation Dose in NM To and From the Patient”

April 2016 Los Angeles, California, American Roentgen Ray Society annual meeting
“Radiation Doses To and From Patients in Nuclear Medicine: Challenges and Solutions”

June 2016 San Diego, California Society of Nuclear Medicine and Molecular Imaging annual meeting, Nuclear Medicine and Radiology Education Session
“Image Interpretation of FDG PET/CT by an Ideal Nuclear Medicine Physician, Part 2”
Education Session in Cross-Training in Nuclear Medicine

May 2017 New Orleans, Louisiana American Roentgen Ray Society annual meeting
“Radionuclide Therapy of Skeletal Metastases and the Growing Role of Theranostics”

International:

Mar 2005 Egyptian Association of Nuclear Medicine Specialists (EANMS) 6th annual meeting, Portsaid, Egypt.
“Oncologic Applications of PET and PET/CT”
“PET/CT Imaging Pitfalls and Artifacts”

Mar 2006 Egyptian Association of Nuclear Medicine Specialists (EANMS) 7th annual meeting, Alexandria, Egypt.
“New Ways for Interpreting PET/CT”
“PET/CT Case Studies”

Jan 2007 Riyadh, Saudi Arabia
“Added Value of PET/CT in Oncology”

Arab Health Meeting, Dubai, United Arab Emirates
“Nuclear Medicine in the 21st Century”

Mar 2008 Nemrock 17th Annual Conference, Ain Soukhna, Egypt
“Cost Effectiveness of PET-Scan in the Management of Common Malignancies”

April 2008 Taiwan PET/CT Symposium, Taichung, Taiwan
“Added Value of PET/CT in Oncology: The SLU Experience”

Mar 2009 Egyptian Association of Nuclear Medicine Specialists (EANMS) 10th annual meeting, Ain Soukhna, Egypt.
“Added Value of FDG PET/CT in GI Cancers”
“Non-Oncologic FDG Uptake in the Head and Neck”

Mar 2009 Egyptian Association of Nuclear Medicine Specialists (EANMS) 11th annual meeting, Hurgeda, Egypt.
“How to Review and Report PET/CT Studies”
“Interpreting Nuclear Medicine Scans: Thinking Outside the Box.”

April 2010 University of Kuwait, School of Medicine Guest Faculty of Nuclear Medicine lecturer.

Feb 2011 University of Kuwait, School of Medicine Guest Faculty of Nuclear Medicine lecturer.

Mar 2012 Kuwait Society of Nuclear Medicine Meeting (KSNM), Salmiya, Kuwait
“Brain Hybrid Imaging”
“Bone Scanning from Planar to PET”
“Interactive Session”

Mar 2012 The Egyptian Society of Nuclear Medicine Specialists (ESNMS), 12th annual meeting, Alexandria, Egypt
“Added Value of SPECT/CT in Nuclear Medicine”
“Updates in Nuclear Neurology”
“Reading with the Experts”

Mar 2013 The Egyptian Society of Nuclear Medicine Specialists (ESNMS), 13th annual meeting, Luxor, Egypt
“Imaging Pitfalls and Artifacts in FDG PET/CT
“Updates in Nuclear Cardiology”
“Interesting case studies”

Aug 2014 11th Congress of the World Federation of Nuclear Medicine and Biology, Cancun, Mexico
“Added Value of True Whole Body FDG PET/CT in Oncology”

Mar 2014 The Egyptian Society of Nuclear Medicine Specialists (ESNMS), 14th annual meeting, Sharm El-Sheikh, Egypt
“Advances in Nuclear Diagnosis and Therapy for Prostate Cancer”
“Interesting Cases”
Digital PET; A New Dawn in PET/CT”

Feb 2015 International Atomic Energy Agency Regional Training Course on Nuclear Oncology using SPECT/CT and PET/CT (Advanced Course), Dubai, United Arab Emirates
“How to Read and Report FDG PET/CT”
“Case Studies and Read with the Experts”
“FDG PET in Sarcoma”
“Radiation Dose To and From Patients in Nuclear Medicine: Challenges and Solutions”
“Added Value of True Whole Body FDG PET/CT in Oncology”
“Bone Scanning from Planar to PET/CT”

Mar 2015 The Egyptian Society of Nuclear Medicine Specialists (ESNMS), 15th annual meeting, Hurghada, Egypt
“Case Studies and Read with the Experts”
“Radiation Dose To and From Patients in Nuclear Medicine: Challenges and Solutions”

April 2015 American Raentgen Ray Society (ARRS) annual meeting, Toronto, Canada. “SPECT/CT in Cardiac Imaging”

Sept 2015 International Atomic Energy Agency Regional Meeting and Workshop on Advanced Nuclear Cardiology SPECT and PET/CT (Advance Course). Cairo, Egypt
“Radiation doses in Nuclear Medicine including Nuclear Cardiology”
“Applications of PET and PET/CT for myocardial perfusion imaging (Rb-82, NH-13)”
“Updates in Nuclear Cardiology”
“Non-cardiac findings in SPECT and SPECT/CT MPI”
“Interesting Case Studies”

Dec 2016 International Atomic Energy Agency Regional Training Course on Advances in Nuclear Medicine for Diagnosis and Therapy in Oncology. Cairo, Egypt
“Bone scanning from planar to PET/CT”
“The need for dual training in PET/CT interpretation”
“Radiation doses in Pediatrics and Adult patients undergoing Nuclear Medicine examinations”
“Theranostics: The future of Nuclear Medicine”
“Therapy in NETs”
“Therapy in Prostate Cancer”
“Read with the expert PET/CT”
“Read with the expert SPECT/CT”
“Radionuclide Therapy for Skeletal Metastases”

Dec 2016 Invited Visit to Maadi Military Hospital. Cairo, Egypt
“Bone scanning from planar to PET/CT”
“The need for dual training in PET/CT interpretation”
“Theranostics: The future of Nuclear Medicine”
“Read with the expert PET/CT”
“Read with the expert SPECT/CT”

May 2017 Nuclear Medicine Council Ministry of Health, Advancements in Nuclear Medicine & Molecular Imaging 2017, Kuwait
“Bone scanning from planar to PET/CT”
“Pediatric bone diseases: From bone SPECT to PET/CT”
“Radiation doses in Pediatrics and Adult patients undergoing Nuclear Medicine examinations”
“Growing role of Nuclear Medicine in Pediatrics”
“PET and SPECT in Epilepsy”
“Radionuclide Therapy for Skeletal Metastases”